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Cardiovascular diseases (CVDs) are a significant health burden with an ever-increasing
prevalence. They remain the leading causes of morbidity and mortality worldwide. The use
of medicinal herbs continues to be an alternative treatment approach for several diseases
including CVDs. Currently, there is an unprecedented drive for the use of herbal
preparations in modern medicinal systems. This drive is powered by several aspects,
prime among which are their cost-effective therapeutic promise compared to standard
modern therapies and the general belief that they are safe. Nonetheless, the claimed
safety of herbal preparations yet remains to be properly tested. Consequently, public
awareness should be raised regarding medicinal herbs safety, toxicity, potentially life-
threatening adverse effects, and possible herb–drug interactions. Over the years,
laboratory data have shown that medicinal herbs may have therapeutic value in CVDs
as they can interfere with several CVD risk factors. Accordingly, there have been many
attempts to move studies on medicinal herbs from the bench to the bedside, in order to
effectively employ herbs in CVD treatments. In this review, we introduce CVDs and their
risk factors. Then we overview the use of herbs for disease treatment in general and CVDs
in particular. Further, data on the ethnopharmacological therapeutic potentials and
medicinal properties against CVDs of four widely used plants, namely Ginseng, Ginkgo
biloba,Ganoderma lucidum, andGynostemma pentaphyllum, are gathered and reviewed.
In particular, the employment of these four plants in the context of CVDs, such as
myocardial infarction, hypertension, peripheral vascular diseases, coronary heart disease,
cardiomyopathies, and dyslipidemias has been reviewed, analyzed, and critically
discussed. We also endeavor to document the recent studies aimed to dissect the
cellular and molecular cardio-protective mechanisms of the four plants, using recently
reported in vitro and in vivo studies. Finally, we reviewed and reported the results of thein.org April 2020 | Volume 11 | Article 4221
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Frontiers in Pharmacology | www.frontiersrecent clinical trials that have been conducted using these four medicinal herbs with
special emphasis on their efficacy, safety, and toxicity.Keywords: herbal medicine, cardiovascular diseases, atherosclerosis, hypertension, medicinal plants,
antioxidants, oxidative stress, inflammationINTRODUCTION
Cardiovascular diseases (CVDs) are diseases of the heart or
blood vessels. CVDs register a global annual toll of more than
17 million deaths. As a result, CVDs remain the world's most
common cause of death and are a major economic and health
burden, worldwide. The World Health Organization (WHO)
reported that CVDs account for 31% of annual global deaths
(World Health Organization, 2017). In Europe, CVDs account
for 45% of all deaths according to the European Cardiovascular
Disease Statistics 2017 (Martinet et al., 2019). The American
Heart Association's current statistics estimate that around half of
the population of the USA has a form of CVD (Benjamin
et al., 2019).
CVDs are a variety of diseases including peripheral vascular
diseases, coronary heart disease (CHD), heart failure, heart
attack (myocardial infarction), stroke, cardiomyopathies,
dyslipidemias, and hypertension, among others (Figure 1)
(Toth, 2007; Reiner et al., 2019). CVDs majorly originate from
a vascular dysfunction, which then leads to organ damage. For
example, the heart can suffer a heart attack, or the brain canin.org 2suffer a stroke due to vascular impairment. Major culprits in
vascular impairment include atherosclerosis, thrombosis, and
high blood pressure (BP). Common risk factors for CVDs
include smoking, unhealthy diet , diabetes mellitus,
hyperlipidemia, elevated levels of low-density lipoprotein
cholesterol (LDL), suppressed levels of high-density lipoprotein
cholesterol (HDL), and hypertension (Figure 1) (World Health
Organization, 2017).
CVDs prevention is favored by a healthy vascular
endothelium. A healthy endothelium exhibits vasodilatory,
anti-atherogenic , and anti- inflammatory propert ies
(Celermajer, 1997). Several risk factors for CVDs lead to
endothelial cell (EC) dysfunction, which has been implicated as
a key event in the pathogenesis of atherosclerosis, coronary
vasoconstriction, and, probably, myocardial ischemia.
Interestingly, EC dysfunction is a reversible phenomenon,
which opens the door for CVD therapies based on its reversion
(Figure 1) (Celermajer, 1997).
Recently, inflammation has been confirmed as a risk factor for
CVDs, especially during atherosclerosis and coronary artery
disease. High levels of high-sensitivity C-reactive protein (hs-FIGURE 1 | Pathological processes involved in the development and progression of CVDs. Several risk factors can predispose to CVDs. These can include
hypertension, smoking, dyslipidemia stemming from an unhealthy diet, or endocrinopathies like diabetes mellitus, hypothyroidism, and aging. The risk factors can
lead to pathological alterations most of which can be due to endothelial dysfunction or VSMC alterations. Endothelial dysfunction or VSMC alterations increase the
risk of developing atherosclerosis and hypertension. Atherosclerosis and hypertension are themselves CVDs risk factors and enhancers for the development of other
CVDs like myocardial infarction, coronary artery diseases, or stroke. VSMC, vascular smooth muscle cell; ECM, extracellular matrix; NO, nitric oxide; eNOS,
endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; Ox-LDL, oxidized low-density lipoprotein.April 2020 | Volume 11 | Article 422
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absolute cardiovascular risk (Ridker et al., 1997; Ridker et al.,
2000), where the CANTOS study, for the first time, established
reduced rates of cardiovascular events following an anti-
interleukin-1 beta (IL-1b) based therapy, independent of
cholesterol levels (Ridker et al., 2017). Furthermore, common
CVDs risk factors, such as diabetes or hypertension, can
predispose to CVDs by the mediation of inflammation
(Dokken, 2008; Aday and Ridker, 2018).
In the case of atherosclerosis, for example, inflammation can
cause EC functional impairment. Dysfunctional ECs allow the
accumulation of low-density lipoprotein (LDL) particles in the
vessel wall intima where they become modified into oxidized LDL.
Oxidized LDL can then activate the dysfunctional ECs to expose
cell adhesion molecules (VCAM-1 and ICAM-1) that bind to and
recruit inflammatory leukocytes (T-cells and monocytes) into the
subendothelial space (Davies et al., 1993; Moore and Tabas, 2011).
These inflammatory blood cells secrete interleukins and cytokines,
produce reactive oxygen species (ROS) and thus form an inflamed
microenvironment within the arterial wall. The inflamed
microenvironment promotes vascular smooth muscle cell
(VSMC) proliferation, matrix build-up, and lipid deposition,
leading to the formation of an atherosclerotic plaque. The
monocytes can reach the intima of the vessel, differentiate into
macrophages, and uptake oxidized LDL to become foam cells
(Tabas et al., 2007; Moore and Tabas, 2011; Douglas and Channon,
2014; Saleh Al-Shehabi et al., 2016; Martinet et al., 2019). Gradual
intimal thickening takes place over the years and continues to
expand causing decreased or complete occlusion of blood flow to
organs, ultimately resulting in CVDs, such as myocardial
infarction or stroke (Maguire et al., 2019). In addition, VSMCs
proliferation leads to narrowing of the arterial lumen and
dysregulation of the vasotone (Douglas and Channon, 2014).
Usually several atherosclerotic plaques form in the intima and
one of these may end up undergoing a necrotic breakdown, leading
to acute luminal thrombosis, blood vessel occlusion, and
cardiovascular complications, including myocardial infarction,
unstable angina (chest pain caused by heart muscle ischemia),
sudden cardiac death, or a stroke (Virmani et al., 2002). As a result,
atherosclerosis is not only a risk factor but also a major contributor
to CVD incidence. Around 50% of all deaths in developed
countries are due to atherosclerosis (Tedgui and Mallat, 2006).
Hypertension also referred to as high BP, is a CVD and a
major risk factor and contributor to other CVDs and other
diseases (2017). Hypertension is an independent predisposing
factor for heart failure, coronary artery disease, stroke,
retinopathy, nephropathy, and peripheral arterial diseases
(Sawicka et al., 2011; NCD Risk Factor Collaboration, 2017).
Most of these diseases are associated with high mortality and
morbidity (Abegaz et al., 2017). Additionally, hypertension is the
single most significant risk factor for atherosclerosis, and any
clinical outcome of atherosclerosis thereof (Sawicka et al., 2011).
Hypertension is a “silent killer” as it does not show symptomsFrontiers in Pharmacology | www.frontiersin.org 3until later stages of the disease (Sawicka et al., 2011). Because of
this, it is not surprising that hypertension affects 1.4 billion
people and accounts for about 9.4 million deaths per year
(Cooper et al., 2017; Egan et al., 2019). Lastly, hypertension
prevalence is estimated to have a 30% worldwide increase by
2025 (Kearney et al., 2005).
The American Heart Association Hypertension Guidelines
define hypertension as a persistent elevation of BP in the arteries
[systolic BP (SBP) higher than 130/diastolic BP (DBP) higher than
80 mm Hg] (Muntner et al., 2018). If an elevated BP is left
unmanaged, it can induce arterial remodeling; the walls of small
vessels thicken, and the vessels lose their elasticity and become
narrower. This process is called arteriosclerosis and can lead to
“target organ damage” (TOD) (Triantafyllidi et al., 2010; Fan et al.,
2017). TOD affects several organs such as the brain, kidney, or
retina and may lead to death (Mensah, 2016; Abegaz et al., 2017).
Arteriosclerosis can be witnessed in coronary vessels where it may
cause a myocardial infarction (Rakugi et al., 1996). In the brain,
arteriosclerosis can cause vessel lumen narrowing, vessel wall
hardening, and blood clot formation, potentially causing a stroke
(Johansson, 1999). Strokes have effects on cognitive and physical
behaviors, and may result in dementia, paralysis, or death (Abegaz
et al., 2017). Nephrosclerosis of the kidney is also due to
arteriosclerosis which stiffens the nephron, ultimately affecting
renal filtration and causing electrolyte imbalances (Bidani and
Griffin, 2004; Lim et al., 2016). Overall, TOD proceed through
hypertension-induced microvascular injuries in the cases of
retinopathy and nephropathy and through hypertension-induced
macrovascular injuries in the cases of stroke and myocardial
infarctions (Nadar, 2011).
BP regulation, and therefore hypertension, depends on two
main factors: cardiac output and systemic vascular resistance.
Increased cardiac output or vascular resistance elevate BP.
Cardiac output is majorly affected by sodium intake, renal
function, and mineralocorticoids. Vascular resistance is affected
by the sympathetic nervous system (SNS), rennin–angiotensin
system (RAS), humoral factors, and local autoregulation
(DiBona, 2013). SNS and RAS exert their effects mainly by
eliciting vasoconstriction and inducing sodium retention.
Humoral mediators can be vasoconstrictors like endothelin,
angiotensin II, catecholamines, or vasodilators, for instance
nitric oxide (NO), prostaglandins, and kinins (Oparil et al.,
2003). Other factors that can modulate BP include blood flow
velocity, blood viscosity, vascular wall stiffness, oxidative stress of
VSMCs or ECs, VSMCs proliferation and shape changes, and EC
health (Rodrigo et al., 2011).
Despite advances in CVD management and treatment, CVDs
still claim more lives than the combination of all cancer forms
(Mozaffarian et al., 2015). As a result, in recent years there has
been major enforcement on CVD prevention (Reiner et al.,
2019). Therefore, new treatment options are urgently
warranted for all types of CVDs, considering the continued
burden stemming from CVDs is still substantial.April 2020 | Volume 11 | Article 422
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MEDICINAL DRUGS
Traditional medicine and ethnomedicine, defined as the study of the
traditional medicines practiced by various ethnic groups, are as old
as human history. Traditional medicine historically relied on natural
resources as medications. Historically, herbs, generally defined as
any form of plant or plant product (Tachjian et al., 2010), and plant
extracts formed the basis of the first drugs used in traditional
medicine systems of many cultures and civilizations. Plants and
herbs have always been a common source of medications, either in
the form of traditional extracts or as pure active compounds
(Fabricant and Farnsworth, 2001). Evidently, nature is a very
important source for finding new drugs that leads to the
treatment of diseases. Famous drugs from herbal and plant
sources include aspirin from the Salix alba L. tree, digoxin
(cardiac glycoside) from Digitalis purpurea, ephedrine from
Ephedra sinica, lovastatin from Monascus purpureus L., taxol
from Taxus brevifolia, reserpine from Rauvolfia serpentina, and
many others (Harvey, 2000; Frishman et al., 2009; Cragg and
Newman, 2013). Interestingly, reserpine is still an effective
treatment for hypertension (Weber et al., 2014). Notably, the
discovery of antimalarial drugs, quinine from the bark of
Cinchona species and artemisinin from Artemisia annua L.,
represent a typical example of how ethnomedicine can guide drug
discovery (Cragg and Newman, 2013).
The earliest records of drugs of natural origin, found in
Mesopotamia (from around 2600 BCE), describe the use of
approximately 1000 plant-derived compounds. The best record
of using natural extracts in therapy is the Egyptians' Ebers Papyrus
(from 1500 BCE), which documents more than 700 natural drugs,
mainly of plant origin. The Chinese Materia Medica record (BCE
1100) describes 52 natural medicinal preparations, and the Indian
Ayurvedic record (BCE 1000) describes more than 800 natural
medicinal extracts (Cragg and Newman, 2013; Otvos et al., 2019).
Hippocrates also applied phytotherapy, or healing with herbs, in
his treatments (Otvos et al., 2019).
In 1985 WHO estimated that around 65% of the world
population mostly depended on plant-derived traditional
medicines (Farnsworth et al., 1985). People in different countries
have come to use identical or comparable plants or herbal
preparations for the prevention and/or treatment of physical and
mental illnesses. Traditional Medicine Centers of the WHO
identified 122 compounds to be commonly used in the Center's
host countries. Interestingly, the 122 compounds have been
reported to derive from only 94 plant species and are used for
similar ethnomedical treatments in the different host countries
(Farnsworth et al., 1985). Examples of such compounds include
galegine, from Galega officinalis L., the base for the synthesis of
metformin and similar bisguanidine-type antidiabetic drugs, and
papaverine from Papaver somniferum which is the base for making
the antihypertensive drug verapamil (Fabricant and Farnsworth,
2001). Commercially, drug production from natural products such
as herbs is a viable commodity, where 39% of the 520 new drugs
approved between 1983 and 1994 were natural compounds or
derived from natural compounds and 60–80% of antibacterial andFrontiers in Pharmacology | www.frontiersin.org 4anticancer drugs were derived from natural products in that same
period (Harvey, 2000).
Despite the many successes of using natural products for drug
production, advances in combinatorial chemistry (in the late
1980s) shifted the focus of drug discovery efforts from natural
products to synthesis at the laboratory bench (Cragg and
Newman, 2013). This is mainly because natural product-based
drug discovery and development is a complex endeavor
demanding costly and highly integrated interdisciplinary
approaches (Davison and Brimble, 2019; Otvos et al., 2019).
Nonetheless, currently the use of natural products as drugs or as
drug discovery platforms is “well and alive” (Newman and
Cragg, 2016). In fact, traditional herbal and plant-derived
extracts are becoming main stream as advances in scientific
research are showing their importance in the prevention and
treatment of diseases (Frishman et al., 2009).
Numerous and chemically diverse secondary metabolites
have been purified from plant bioactives and have been
optimized for exerting a biological effect, nonetheless, they are
still away from exhaustive investigation for clinical use. However,
recent published scientific evidence, technological advances, and
research trends clearly point that naturally-derived compounds
will be major sources of new drugs (Davison and Brimble, 2019;
Otvos et al., 2019). This has provided a driving cause for the
renewed popularity of traditional herbal and plant-derived
medications among researchers, despite developments in
combinatorial chemical synthesis and the production of
modern synthetic drugs (Frishman et al., 2009).
Another reason for the regained interest in medicinal plant
products is that, in their attempts to control diseases amid scarce
socioeconomic resources, rural communities in developing
countries have found resort in traditional herbal and plant-
derived remedies. This is due to several factors, but in particular
to the fact that plant-based medicines are a cheaper alternative with
fewer side effects (Frishman et al., 2009; Tabassum and Ahmad,
2011). Herbal and plant remedies are not only economical, but they
also contain thousands of bioactive components that have known
therapeutic applications (Pan et al., 2013). Additionally, because
herbs are viewed as food products, they are not subject to the same
surveillance and regulation as conventional drugs. Moreover, herbal
remedies are viewed by patients as being natural and therefore safe.
However, more research efforts are required to validate the efficacy
and the safety profile of such medicaments since many have adverse
outcomes that can sometimes have life-threatening effects. It should
also be noted that there is concern regarding herb–drug interaction
(Tachjian et al., 2010; Anwar et al., 2016; Yuan et al., 2016).
One more reason for the revived interest in natural products is
that the biological activity and structural diversity of natural
products are unmatched by any available synthetic drug screening
library (Davison and Brimble, 2019). Natural products have been
selected by nature for bioactivity, over millions of years. As a result,
natural product screening libraries need not be superfluously big, as
is the case with synthetic drug screening libraries. In addition,
natural products need only minor structural changes to optimize
their drugability (Harvey, 2000; Gerry and Schreiber, 2018). As
such, natural products offer “privileged scaffolds” and serve asApril 2020 | Volume 11 | Article 422
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candidate drug libraries (Davison and Brimble, 2019). Recent
progress has focused on improving the potency, selectivity, and
pharmacokinetics of bioactive natural products through structural
modifications, which has led to the production of novel drug-like
lead compounds. These structural changes are often required, as
natural products usually show unfavorable toxicities and
pharmacokinetics, limiting their clinical potential (Gerry and
Schreiber, 2018; Davison and Brimble, 2019). Overall, natural
products have been the single most productive source of drug
leads even though little of nature's biodiversity has been tested for
biological activity yet (Harvey, 2000).
We therefore address and expose the general rationale for
using medicinal herbs in the therapy of diseases in general and
CVDs in particular. Then, we move to discuss the medicinal
potentials of four traditional herbs (Ginseng, Ginkgo biloba,
Ganoderma lucidum, and Gynostemma pentaphyllum) for the
treatment of CVDs, which are getting increasing popularity due
to their commercial commodity in many markets worldwide and
to their proven therapeutic potential in several settings including
cardiovascular conditions. We describe and critically discuss
their therapeutic benefits in terms of molecular, cellular, and
metabolic properties in the context of CVDs. In addition, we
highlight the major clinical trials in which these four herbs have
been used, with an emphasis on their efficacy and safety.MODERN MEDICINE MANAGEMENT OF
ATHEROSCLEROSIS AND
HYPERTENSION
Current health care guidelines emphasize prevention to
minimize the risk of CVDs (Reiner et al., 2019). This is carried
out by addressing the major CVD risk factors and trying to
minimize their adverse outcomes. In atherosclerosis, most
therapeutic approaches aim to control hypertension and
hyperlipidemia or modulate hemostasis in order to avoid
thrombotic complications (Weber and Noels, 2011).
Hypercholesterolemia is a major contributor in atherosclerosis,
so current conventional therapeutic approaches rely significantly
on lowering LDL levels using statins (Ridker et al., 2017; Aday
and Ridker, 2018; Reiner et al., 2019). In cases where statin
therapy does not yield a significant reduction in LDL levels, an
LDL-absorption inhibitor can be used, alone or in combination
with statins depending on patient response. Clinical trials have
clearly shown that such therapies are effective in lowering CVD
risk (Reiner et al., 2019). Recently, pro-protein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors were approved by
the regulatory bodies as a drug that can lower LDL level, and are
recommended for use in patients with heart problems, where
statins were not effective at lowering LDL levels (Ridker et al.,
2017; Aday and Ridker, 2018). The CANTOS clinical trial (2017)
has provided evidence that in patients with elevated
inflammation (hsCRP > 2 mg/L), a combination therapy of
statins and canakinumab (IL-1b antibody) may be necessary to
lower atherosclerosis risk (Ridker et al., 2017; Aday and Ridker,Frontiers in Pharmacology | www.frontiersin.org 52018; Reiner et al., 2019). Prior to the recommendations of the
CANTOS study, conventional therapy regimens have neglected
the role of inflammation in atherosclerosis (Weber and Noels,
2011). It is very important to highlight that complementary and
alternative medicine (CAM), including herbal remedies, have
already tackled the inflammatory arm of atherosclerosis much
earlier than the results of the CANTOS study (Frishman et al.,
2009; Orekhov et al., 2013; Al-Shehabi et al., 2016), giving a hint
as to why American patients visited CAM providers much more
than primary care physicians (Eisenberg et al., 1998; Tachjian
et al., 2010). Of relevance to this discussion is that herbal
remedies are the most common type of CAM among CVD
patients (Yeh et al., 2006; Tachjian et al., 2010).
Modern therapy regimens for hypertension involve
controlling BP elevations in hypertensive patients. This usually
requires the use of multiple antihypertensive drug agents in the
majority of these patients (Guerrero-Garcia and Rubio-Guerra,
2018). Multiple classes of antihypertensive agents are available
thus offering a practitioner the ability to prescribe highly effective
drug combinations in order to reduce BP and protect target
organs (Stewart et al., 2019). This combination therapy is of
distinctive importance in resistant hypertension, which is highly
prevalent worldwide (Noubiap et al., 2019; Samaha et al., 2019).
The major drug classes available for the management of
hypertension are thiazide diuretics, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor II blockers, and
calcium channel blockers (Susalit et al., 2011; Munoz-Durango
et al., 2016). Vasodilators, aldosterone antagonists, b-blockers,
a-blockers, renin inhibitors, and central-acting agents are other
agents that are occasionally used (Omboni and Volpe, 2018).
These agents lower BP in patients and reduce their risk of
hypertension-related CVD events, but do not prevent them
thereby justifying the use of hypertension combination
therapies (Rizvi, 2017).
Despite the availability of the aforementioned medications in
modern-day health care systems, high BP is managed in only
34% of the patients (August, 2004; Wang and Xiong, 2012). Such
an aspect appears to be mainly related not only to the cost of
antihypertensive agents (Susalit et al., 2011), but also to their
availability and accessibility (Wang and Xiong, 2012), their
unwanted side effects (Susalit et al., 2011; Wang and Xiong,
2012), and their low patient compliance with the required dose
(August, 2004). For these factors hypertension patients seek
CAM medications, especially herbal-based medicaments to
treat their CVDs in general and hypertension in particular
(Yeh et al., 2006; Tachjian et al., 2010; Al Disi et al., 2016).HERBAL MEDICINE MANAGEMENT OF
ATHEROSCLEROSIS AND
HYPERTENSION
Herbal extracts and their derivatives can favorably modulate and
ultimately ameliorate the molecular events that contribute to
hypertension or atherosclerosis, the two major contributors to
CVDs incidence. Herbal remedies contain numerous bioactivesApril 2020 | Volume 11 | Article 422
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fact, herbal remedies can have antioxidant, vasorelaxant, anti-
inflammatory, anti-proliferative, or diuretic effects. Herbal
remedies can also prevent VSMC phenotypic switching, inhibit
endothelial dysfunction, platelet activation, lipid peroxidation,
ROS production, and macrophage atherogenicity. Because of
such a wide range of molecular and cellular targets, herbal
preparations can be used to treat and manage a range of
CVDs. For example, Salvia miltiorrhiza (Red sage), an annual
sage traditionally used in Chinese medicine, has been used to
treat a plethora of CVDs including CHD, myocardial infarction,
atherosclerosis, and angina pectoris. The active compounds are
mainly utilized as the dried root of the plant rhizome named
Danshen (Gao et al., 2012). The plant bioactive compounds are
the lipo-soluble Tanshinones and the water-soluble Phenolics
(Ren et al., 2019). S. miltiorrhiza extracts have shown strong
antioxidant capabilities with a high ability to scavenge free
radicals, which seems the base of its strong cardio- and
vascular-protective potential (Zhao et al., 2006).
Salvianolic acid B, one of the pure compounds that can be
extracted from S. miltiorrhiza, is effective against fibrosis and
ischemia–reperfusion injury (Lay et al., 2003). Danshen has a
protective effect against homocysteine-induced adverse effects,
where homocysteine imbalance is a high-risk factor for vascular
diseases (Chan et al., 2004). In combination with Pueraria
montana var. lobata. (Kudzu), Danshen has showed potent
anti-hypertensive effects (Ng et al., 2011). In one clinical trial,
Danshen capsules (1000 mg twice daily for 12 weeks) were able
to significantly reduce SBP and pulse rate in patients with
uncontrolled mild to moderate hypertension and under
conventional antihypertensive treatment. It has also been
found to be well-tolerated and considered to be safe in patients
with hypertension (Yang et al., 2012).
Astragalus membranaceus (Synonym Astragalus propinquus
Schischkin. in the Missouri Botanical Garden plant list),
another Chinese herb, contains Astragaloside IV, which is the
plant major bioactive compound widely used as an antioxidant
and for protection against ischemic-associated CVDs (Zhang
et al., 2006). A. membranaceus extract has been found to
maintain cardiac functions by improving energy metabolism
and inhibiting the production of free radicals in a myocardial
ischemia reperfusion rat model (Zhou et al., 2000). By decreasing
the levels of the oxidative stress marker malondialdehyde
(MDA), maintaining superoxide dismutase (SOD) activity, and
reducing free radicals-induced myocardial cell injury, A.
membranaceus can also improve cardiac function and provide
cardioprotection in a myocardial ischemic rat model (Ma et al.,
2013). A. membranaceus extract also has angiogenic effects in the
ischemic injury rat model (Zhang et al., 2011). Astragaloside IV
has been found to provide a positive inotropic effect improving
left ventricular ejection in patients with congestive heart failure
(CHF) (Luo et al. , 1995). The polysaccharide of A.
membranaceus has also been shown to reduce insulinFrontiers in Pharmacology | www.frontiersin.org 6resistance and to possess anti-obesity and hypolipidemic effects
(Mao et al., 2009).
Allium sativum (Garlic) is a classic example of herbs used in
CVDs management and is quite known for its multifaceted
properties against CVD-associated conditions such as
hyper tens ion , ox idat ive s t res s , inflammat ion , and
hyperlipidemia (Ashraf et al., 2013; Jeong et al., 2016;
Thomson et al., 2016). Indeed, by reducing total cholesterol
and LDL levels, decreasing the content of lipid in arterial cells
and inhibiting VSMCs proliferation, garlic can be used to
manage atherosclerosis and hyperlipidemia (Sun Y. et al.,
2018). Owing to its endothelial NO synthase (eNOS)-
modulated vasorelaxation ability, Crataegus oxyacantha
(Synonym Crataegus rhipidophylla Gand. Common name
Hawthorn) is another example of herbs commonly used to
manage hypertension (Brixius et al., 2006). Another herb,
Crocus sativus (Saffron), can block Ca2+ channels via
endothelium-independent mechanisms providing another
vasodilator mechanism, in addition to its eNOS activating
ability (Razavi et al., 2016). Among other medicinal plants
Hibiscus sabdariffa (roselle), is known to reduce BP using its
ability to inhibit ACE (Ojeda et al., 2010), while Camellia sinensis
(Tea) extracts can reduce hypertension by significantly
increasing brachial artery flow-mediated dilation (FMD) (Ras
et al., 2011). Rosemary (Rosmarinus officinalis) exhibits
neuroprotection by acting against ischemic stroke-associated
cerebral insufficiency, which is characterized by a reduction of
localized blood flow in the brain. Through its anti-inflammatory
properties, rosemary can decrease the expression of inducible
NO synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as
that other pro-inflammatory enzymes and mediators
(Seyedemadi et al., 2016). The use of herbal plants extends to
include CHF and atrial arrhythmias. Digitalis, extracted from the
dried leaves of the common foxglove, is a potent inhibitor of
Na+/K+-ATPase and can cause depolarization leading to smooth
muscle contraction and vasoconstriction and hence can
strengthen muscle heart contractions (Liu et al., 2016).
Given all these restorative abilities, it is not surprising that
herbal remedies are being absorbed into evidence-based
medicine for the prevention and/or treatment of CVDs. Table
1 lists common herbal remedies and the form of CVDs that they
can help alleviate.
Although herbs have been widely used in both traditional and
modern medicine, a limited number of reviews that gather them
and comprehensively focus on their mechanisms of action and
safety in the context of CVDs are present. Many plant-based
compounds appear to have cardiovascular protective effects,
nevertheless, among the most effective compounds are
flavonoids, terpenoids, saponins, and polysaccharides. These
highly effective compounds are major components of four of
the most recognized herbal preparations namely: Ginseng,
Ginkgo biloba, Ganoderma lucidum, and Gynostemma
pentaphyllum, which we decide to cover in this review.April 2020 | Volume 11 | Article 422
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Ginseng is an anciently cultivated plant (2000 years ago) partly
due to its ritual use (Figure 2). Ginseng use in traditional
medicine goes back to 20 centuries ago (Kim, 2012), but its use
in Western medicine dates back to the early 20th century by two
British physicians F. Porter Smith and G.A. Stuart who were
exploring Chinese herbal remedies at the time (Shih-Chen et al.,
1973). Ginseng habitats include Asian countries such as Korea,
China, Japan, and Vietnam, and North American countries,
mainly Canada and the United States. Korean red ginseng
(KRG; Panax ginseng C.A. Mey.), Chinese ginseng (Panax
notoginseng Burkill; F.H.Chen.), American ginseng (Panax
quinquefolium L.), and Japanese ginseng (Panax japonicas C.A.
Mey.) represent the most commonly used ginsengs.Frontiers in Pharmacology | www.frontiersin.org 7Usually the roots of 5 to 7-year-old plants are either air-dried
under the sun yielding “white ginseng” or steam-treated at 98–
100°C for 2–3 h and then sun-dried to produce the “red ginseng”
(Kim et al., 2000). During steaming, ginseng chemical
constituents undergo changes that make red ginseng more
pharmacologically effective than white ginseng (Kim et al.,
2000). Currently, ginseng is prepared and used either in a
liquid form: oil extracts or tea; or in a solid form: tablets,
capsules, or dried roots (Valli and Giardina, 2002). However,
extracts of ginseng root, berry, and leaf have been repeatedly
demonstrated to have anti-obesity, anti-hyperglycemic, anti-
hypertensive, insulin sensitization, and anti-hyperlipidemic
effects (Kim, 2012).
More than 300 bioactives have been isolated from Ginseng.
Ginsenosides, which are triterpene saponins, are the most bioactive
constituents isolated from Ginseng extracts (Mahady et al., 2000).
Of the 40 ginsenosides isolated so far, Rb1, Rg1, Rg3, Re, and Rd are
the most frequently studied. Rg3, Rg5, and RK1 are unique to the
red Korean Ginseng (Figure 2) (Lee and Kim, 2014). Research into
Ginseng and its constituents has flourished so that currently there is
a journal dedicated to Ginseng research: Journal of Ginseng
Research (https://www.journals.elsevier.com/journal-of-ginseng-
research). The study of the purified individual ginsenosides
rather than the whole Ginseng root extract has gained recent
interest (Kim, 2012). Ginseng and its ginsenoside constituents
have vasorelaxation, anti-oxidation, anti-inflammation, and anti-
cancer activities (Kim, 2012; Choi J. et al., 2013).
Ginseng at the Bench: Mechanism of
Action in CVDs
In the context of CVDs, Ginseng has been used to manage
hypertension. Ginseng has hypotensive effects due to its effect in
the improvement of arterial functions. Interestingly,
ginsenosides facilitate vasorelaxation of different vessels: rat
aortas (Kim et al., 1999a), murine coronary arteries (Pan et al.,
2013), and monkey cerebral arteries (Toda et al., 2001). Ginseng
can increase eNOS expression and NO production while
ginsenoside Rg3 activates eNOS (Valli and Giardina, 2002;
Jang et al., 2011; Hong et al., 2012; Pan et al., 2013; Lee K.
et al., 2016). KRG induces NO-dependent vasorelaxation
improving vascular tone. These effects are mediated by the
inhibition of arginase activity, the increase of NO generation,
and the enhancement of eNOS dimer formation (Shin W. et al.,
2013). The Panax ginseng G115 extract has also been shown to
inhibit ACE activity in human umbilical vein endothelial cells
(HUVECs) and angiotensin I-induced contractions of bovine
mesenteric arteries (Persson et al., 2006). Other Ginseng CVDs
management properties are its anti-oxidant (Lee et al., 2019a),
anti-inflammatory (Keum et al., 2003; Shin Y. et al., 2013), and
anti-hyperlipidemic (Park et al., 2005) effects, along with its
ability to regulate Ca2+ channels (Lee and Kim, 2014).
The ginsenoside Rg3 can increase NO and cGMP levels,
activate Ca2+-gated potassium channels, inhibit ACE activity,
and block Ca2+-gated channels (Kim et al., 1999b; Persson et al.,
2006; Park J. et al., 2014). Ginseng has also demonstrated an anti-
inflammatory role by inhibiting the activation of activatorTABLE 1 | Some herbal remedies traditionally used for the treatment of different
forms of CVDs.
CVD form Examples of herbal remedies used
Atherosclerosis and
hyperlipidemia
Garlic (Allium sativum)
Commiphora mukul
Monascus purpureus
Berberine (active compound of Coptis chinensis)
Systolic hypertension Garlic (Allium sativum)
Rauvolfia serpentina
Panax species (Ginseng)
Stephania tetrandra
Veratrum species alkaloids
Ligusticum wallichii (Synonym of Ligusticum
striatum DC)
Hawthorn from Crataegus oxyacantha
Camelia sinensis
Andrographis paniculata
Apium graveolens
Bidens pilosa L.
Crocus sativus
Cymbopogon citratus
Hibiscus sabdariffa
Nigella sativa
Urtica dioica
Viola odorata
Mentha longifolia
Salvia miltiorrhiza
Uncaria Rhynchophylla
Venous insufficiency Aesculus hippocastanum
Ruscus aculeatus
Cerebral insufficiency Ginkgo biloba
Rosmarinus officinalis
Angina pectoris Crataegus species
Panax notoginseng
Salvia miltiorrhiza
Congestive heart failure Digitalis purpurea
Digitalis lanata
Crataegus species
Adonis microcarpa and Adonis vernalis
Berberine (active compound of Coptis chinensis)
Salvia miltiorrhizaThe herbal remedies refer to the plant extract, unless otherwise indicated where the
remedy may be a purified or partially purified active ingredient of the plant extract. Data
were obtained from published data in (Valli and Giardina, 2002; Frishman et al., 2009; Al
Disi et al., 2016; Al-Shehabi et al., 2016; Samaha et al., 2019).April 2020 | Volume 11 | Article 422
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reducing the expression of COX-2, IL‐6, IL‐1b, and tumor
necrosis factor‐a (TNF‐a) (Keum et al., 2003; Shin Y. et al.,
2013). In macrophages, Baek et al. demonstrated that each
fraction of the KRG exerts anti-inflammatory actions through
a different mechanism. For instance, the saponin fraction
significantly suppressed NO production and reduced the
expression of inflammatory genes such as iNOS, COX-2, TNF-
a, and interferon-b. In contrast, all extracts, including water
extracts, saponin, and non-saponin fractions, inhibit the activity
of the kinase TBK1 and suppress both nuclear translocation and
transcriptional activity of its downstream effector interferon
regulatory factor 3 (IRF3) (Baek et al., 2016).
By inhibiting diacylglycerol liberation, dietary supplementation of
KRG lowers blood cholesterol levels and reduces the formation of
atherosclerotic lesions induced by a high cholesterol diet in rabbit
(Hwang et al., 2008). Again, by up-regulating the adenosine
triphosphate-binding cassette transporter A1, the saponin fraction
of P. notoginseng can attenuate cholesterol esters in foam cells (Jia
et al., 2010). In addition, Ginseng has shown a potent in vivo
antithrombotic effect, which may be due to an antiplatelet activity
rather than an anticoagulation activity, indicating that Ginseng intake
may be beneficial for individuals with high risks of thrombosis and
CVDs (Lee and Kim, 2014). In this context, the dihydro-ginsenoside
Rg3 has been reported to potently inhibit platelet aggregation through
the modulation of downstream intracellular signals such as cAMP
and extracellular signal-regulated kinase 2 (Lee et al., 2008).Frontiers in Pharmacology | www.frontiersin.org 8In Vivo Preclinical Evaluation of Ginseng in
Animal Models of CVDs
Ginseng's hypotensive effects have been extensively
demonstrated (Valli and Giardina, 2002; Lee et al., 2012;
Mucalo et al., 2013; Al Disi et al., 2016). For example, Ginseng
can reduce adrenal catecholamines secretion in hypertensive rats,
thus contributing to vasorelaxation (Jang et al., 2011). However,
there are reports of Ginseng being hypertensive (Jang et al., 2011;
Kim, 2012). In fact, Ginseng may have biphasic concentration-
dependent effects. Low doses of ginseng raise BP, while higher
concentrations repress BP (Jang et al., 2011), a phenomenon that
could be due to the varied action of different Ginseng extract
constituents (Valli and Giardina, 2002).
Through their antioxidant properties, ginsenosides also mediate
anti-hypertensive and anti-atherosclerotic effects. Ginsenosides
exhibit free radical scavenging and metal ion chelating abilities.
For instance, the lipid-soluble and water-soluble extracts from the
North American Ginseng exhibit strong antioxidant activity (Kitts
et al., 2000). Lu et al. showed that Rb1 could significantly and
specifically alleviate hydroxyl radical and hypochlorous acid radical
damaging effects (Lu et al., 2012). Aged rats, supplemented with the
North American Ginseng for four months, had decreased
production of both ROS and age-related oxidative damage in
proteins of the heart and muscle fibers, a phenomenon mediated
by SOD and glutathione peroxidase (GSH-Px) activation (Fu and Ji,
2003). The ginsenoside Rg3 can ameliorate mitochondrial
dysfunction and promote enhanced expression of antioxidantA
B
C
FIGURE 2 | Ginseng. (A) Roots have the healing properties (from https://pngtree.com/freepng). (B) Chemical structure of Ginsenosides. (C) Ginsenosides
protopanaxadiol (PPD) and Ginsenoside protopanaxatriol (PPT). R1 and R2 are side chains in different ginsenosides. Glc, glucose; Ara, arabinose; Rha, rhamnose.April 2020 | Volume 11 | Article 422
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(Nrf2) and the heme oxygenase-1 (HO-1) (Lee et al., 2019a). By
reducing hypertension- and atherosclerosis-associated
inflammatory states, Ginseng can reduce CVD risk. To address
the anti-inflammatory effects of Ginseng, Mohammadi et al. carried
out a meta-analysis of data from randomized controlled trials. They
report that Ginseng supplementation significantly lowered the levels
of two key pro-inflammatory mediators IL‐6 and TNF‐a
(Mohammadi et al., 2019). By modulating angiogenesis
(decreased VEGF-A and FGF-2 expression), inflammatory
(decreased CD68, TNFa, and MCP-1 expression) and matrix
metalloproteinase (MMP) activity, Ginseng can inhibit
ovariectomy-induced obesity, adiposity, and adipocyte hypertrophy
(Lee H. et al., 2016).
Ginseng can lower the risk of atherosclerosis by inducing a better
lipid profile. Ginseng's beneficial effects on lipid metabolism have
been described more than three decades ago (Qureshi et al., 1983;
Yamamoto et al., 1983). In humans and rats, red Ginseng
supplementation improves lipid profiles by diminishing the total
plasma levels of cholesterol, triglycerides, LDL-C, free fatty acids
(FFA), and platelet adhesiveness and increasing HDL-C levels in
total plasma (Deng et al., 2017; Singh et al., 2017). In rats, black
Ginseng can ameliorate hypercholesterolemia by interfering with
the expression of cholesterol metabolism genes (Saba et al., 2016). In
addition, lipid profiles tend to improve in diabetic rats receiving
Ginseng, suggesting that Panax ginseng can ameliorate diabetes
mellitus-initiated dyslipidemias (Deng et al., 2017; Abdelazim et al.,
2018). By modulating the secretion of lipoproteins, Ginseng can
reduce the microsomal triglyceride transfer protein (MTTP) (Oh
et al., 2012), which plays an essential role in lipid metabolism and
transport (Deng et al., 2017).
KRG works as an agonist of peroxisome proliferator-activated
receptor (PPAR), which is known to improve atherogenic
dyslipidemia by augmenting liver PPAR-a mRNA and raising
lipoprotein lipase mRNA levels (Park et al., 2005). Consistent
with this study, Shin et al. demonstrated that Ginseng could
prevent obesity and dyslipidemia in high-fat diet (HFD)-fed
castrated mice. These processes were mediated through the
inhibition of adipogenesis-related genes expression (SREBP-1C,
PPAR-g, FAS, SCD1, and ACC1) in visceral adipose tissues (Shin
and Yoon, 2018). Ginseng extracts or ginsenosides can act
synergistically with testosterone to further inhibit dyslipidemia
(Shin and Yoon, 2018). Mollah et al. also showed that Ginseng
can improve lipid profiles via PPAR pathway activation (Mollah
et al., 2009; Yang and Kim, 2015). Further, ginsenoside Rg1 can
activate the promoter of PPAR-a leading to the expression of its
target genes carnitine palmitoyltransferase-1 (CPT-1) and acyl-
CoA oxidase (ACO), which are involved in fatty acid oxidation.
These findings indicate that Rg1-induced improvement of lipid
profiles may be associated with increased fatty acid oxidation
through PPAR-a activation (Park et al., 2011).
Ginseng to the Clinic
Numerous clinical trials have been conducted to assess the
cardio-protective and beneficial effects of Ginseng and its
constituents in CVD treatment. Checking the clinical trials onFrontiers in Pharmacology | www.frontiersin.org 9Ginseng, its extracts or ginsenosides on the U.S. National Library
of Medicine www.clinicaltrials.gov reveals that there are 162
Ginseng clinical trials. Of the 162 trials, 47 were Phase 3 or 4
trials, 97 have been completed and the rest are ongoing.
Importantly, a significant number of these trials addresses
CVDs. For example, eight trials addressed hypertension, five
addressed arterial occlusive diseases, and another five addressed
strokes. One such clinical trial examined the vasorelaxation
effects of Asian Ginseng (AG) and its ability to modulate
vascular function. Trial participants were randomized to either
the selected AG extract or placebo groups and received a daily
dose of 3 g of AG for 12 weeks in combination with their usual
antihypertensive and anti-diabetic therapy. Combining AG
extract with conventional therapy in diabetics patients with
concomitant hypertension decreased arterial stiffness and
attenuated SBP (Mucalo et al., 2013). Another clinical trial
found that Rg3 from KRG lowers central and peripheral
arterial pressures in healthy adults (Jovanovski et al., 2014). In
an acute, randomized, placebo-controlled, double-blind,
crossover trial on participants with type 2 diabetes mellitus
(T2DM), Shishtar et al. showed that acute administration of
Korean white Ginseng appears to be safe and exhibits beneficial
effects on the augmentations index, a cumulative indicator of
arterial health (Shishtar et al., 2014a).
A 12-week intervention with KRG was conducted in patients
with impaired fasting glucose, impaired glucose tolerance, or
newly diagnosed with T2DM. Subjects were randomized in a
double-blind, placebo-controlled trial. The trial results showed
that 12 weeks of intervention with KRG supplementation (5 g/
day) led to normalization of whole blood and serum glucose
levels as well as serum insulin and CRP concentrations (Bang
et al., 2014). Administration of Panax Ginseng extract (PGE) for
8 weeks (6 g/day) decreased serum triglycerides and total
cholesterol and LDL levels, while increasing HDL levels. These
results were attributed to PGE potent antioxidant effects (Kim
and Park, 2003). In accordance, the effects of a low-dose (3 g/
day) and a high-dose (6 g/day) of KRG supplementation for 8
weeks on antioxidant enzymes and oxidative stress markers in
humans were assessed in a randomized, double-blind, placebo-
controlled trial. Increased GSH-Px, SOD, and CAT activities
were found in the high-dose group as compared to the placebo
group. Plasma oxidized-LDL levels and DNA tail length and tail
moment were significantly decreased in both high and low dose
groups but increased in the placebo group. This led to the
conclusion that supplementation with KRG upregulates
antioxidant enzymes activities and consequently attenuates
lymphocyte DNA damage (Lee et al., 2012).
The efficacy of Ginseng against T2DM is well documented. A
meta-analysis of eight clinical trials showed that administration of
Ginseng, in comparison to the placebo, improves fasting glucose
levels, postprandial insulin levels, and insulin resistance. In these
patients, ginseng was able to improve blood lipid profile lowering
triglycerides, total cholesterol, and LDL levels. This meta-analysis
concluded that Ginseng supplementation can improve the control
of glucose levels and insulin sensitivity in patients with T2DM (Gui
et al., 2016). Another meta-analysis of 16 randomized clinical trialsApril 2020 | Volume 11 | Article 422
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glycemic index by reporting the ability of Ginseng to reduce fasting
blood glucose in both patients with and without diabetes (Shishtar
et al., 2014a; Shishtar et al., 2014b). Interestingly, when Ginseng is
combined with conventional drugs, its efficacy in the management
of hypertension is more pronounced. Indeed, combining AG extract
with conventional therapy in diabetic patients with concomitant
hypertension decreased arterial stiffness and attenuated SBP
(Mucalo et al., 2013).
Despite the numerous clinical trials showing the efficacy of
Ginseng in CVDs management, this aspect yet remains
controversial. In fact, some studies could not demonstrate
Ginseng's beneficial effects against CVD. For example, a meta-
analysis of 17 randomized clinical trials (1381 participants) found
no significant effect of AG on arterial BP and hence no effect on
CVDs risk (Komishon et al., 2016). Another clinical trial concluded
that KRG intake (3 g/day) for 3 weeks had no beneficial effects on
arterial stiffness in subjects with hypertension (Rhee et al., 2011).
Yet, as mentioned above, when KRG was combined with
conventional therapy it was able to control hypertension (Rhee
et al., 2011).
Thus, Ginseng appears to be efficient in regulating several
lipid profile parameters, and has shown positive effects in
patients with T2D. Also, the efficacy of Ginseng in the
management of hypertension is well documented when
combined with conventional hypotensive medications.Safety, Toxicity, and Side Effects of
Ginseng
As mentioned earlier, the claimed safety of medicinal herbs has
to be handled cautiously, and on a case-by-case basis for each
herbal preparation. The safety of Ginseng has been
experimentally approached using animal models and human
clinical studies (Mahady et al., 2000). An abundant number of in
vitro and in vivo studies, as well as human clinical trials have
pointed out that Ginseng extracts have negligible side effects
(Park K. et al., 2014). Few unfavorable symptoms were reported
following long periods of administration of high doses of
Ginseng extracts. This included morning diarrhea, skin
eruption, nervousness, sleeplessness, hypertension, edema,
decreased appetite, depression, and hypotension (Siegel, 1979;
Kiefer and Pantuso, 2003). A systematic review on PGEs in
randomized controlled trials highlighted the safety of Ginseng.
The review identified 40 studies where adverse effects were
reported, but analysis revealed that out of the 40 studies, 16
studies showed no adverse events and 24 studies had 135 minor
events (Shergis et al., 2013). Lee et al. reported that P. ginseng
extract (1 or 2 g/day) supplemented over the course of 4-weeks
was safe, tolerable, and free of toxic effects in healthy volunteer
subjects. Only non-significant changes were observed in
hematological and biochemical tests (Lee et al., 2012).
Recently, Song et al. performed a large-scale clinical study with
1000 participants randomly divided into two groups; a placebo
and a group supplemented with 2 g/d of KRG. Their findings
asserted the safety and tolerability of KRG (Song et al., 2018).Frontiers in Pharmacology | www.frontiersin.org 10Along the same lines, the mutagenic and toxicity potentials of
tissue cultured mountain Ginseng adventitious roots
(TCMGARs) were tested. TCMGARs did not exhibit any
mutagenic properties when tested in diverse strains of
Salmonella typhimurium and Escherichia coli. This was further
shown in vivo without any evidence of TCMGARs mutagenicity,
such as chromosomal aberration and micronucleus appearance,
in mice exposed to TCMGARs (Murthy et al., 2018). All these
studies confirm the biosafety and non-toxicity of Ginseng at an
average dietary consumption.
Ginseng supplements have also shown certain clinically
relevant patterns of adverse cardiovascular reactions. There are
reports of numerous cases where prolonged Ginseng use or
misuse has led to potential side effects related to cardiovascular
events such as increased BP (Coon and Ernst, 2002), long QT
syndrome, or atrial fibrillation (AF) (Paik and Lee, 2015). For
example, in a young man, 3-year Ginseng supplementation has
been found to correlate with hypertension, shortness of breath,
dizziness, and inability to concentrate, symptomatology that
disappeared and did not recur after stopping the supplements.
In another instance, a hypertensive female receiving no other
medication than Ginseng (Ginzin tablets; Ferrosan) reported an
increase in BP rather than a decrease. Interestingly, such
Ginseng-associated BP increase remitted going back to pre-
treatment levels 4 days after the cessation of Ginseng intake
(Coon and Ernst, 2002). Although the observed effects appeared
not to be clinically relevant, in a 30-subjects prospective,
randomized, double-blind, placebo-controlled study, Ginseng
was found to prolong the QTc interval and reduce DSB in
healthy adults as early as 2 h after consumption (Caron et al.,
2002). A 43-year-old healthy woman without familial history of
sudden cardiac death and negative test of long QT mutations
developed a long QT syndrome followed by polymorphic
ventricular tachycardia. The woman admitted to the hospital
revealed she was consuming 70 cL of caffeine and 4 L of Korean
Panax ginseng daily for 6 months. Upon stopping Ginseng
consumption, the patient had no subsequent events. Yet, it is
not proven whether a higher dose of Ginseng or a synergistic
effect of caffeine could further prolong QT leading to malignant
dysrhythmias (Torbey et al., 2011). Additionally, an AF with
slow ventricular rate developed after taking AG for 1-week in an
83-year old woman with chronic renal disease (Liao et al., 2010).
Nevertheless, all these mentioned episodes are considered rare
adverse reactions that mostly depend on inter-variability
between patients (Paik and Lee, 2015).
Ginseng has been reported to interact with several drugs, yet
its interaction with warfarin (blood-thinning drug) is the most
documented (Yuan et al., 2004; Chua et al., 2015). A randomized,
double-blind, placebo-controlled trial using 20 healthy patients
concluded that a 2-week intake of American Ginseng (2 g/d; 1 g
twice daily) significantly reduced peak international normalized
ratio (INR) and peak plasma warfarin levels (Yuan et al., 2004).
In a recent study performed on rats, ginsenosides were reported
to significantly enhance the activity of two enzymes known to
metabolize warfarin, P450 CYP3A4 and P450 CYP2C9, restoring
the levels of coagulation factors II and VII and that of the proteinApril 2020 | Volume 11 | Article 422
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The combined use of Panax ginseng with the monoamine
oxidase inhibitor, phenelzine (Nardil), may result in manic-like
symptoms (Vogler et al., 1999). Finally, although the efficacy and
safety of Ginseng has been evidenced in numerous clinical
studies, additional well-designed, large-scale randomized
control trials are needed.GINKGO BILOBA
Ginkgo biloba, also known as the maidenhair tree in English due to
its resemblance to the foliage of the Maidenhair fern (Figure 3),
is among the oldest seed plants. It is regarded as a “living fossil”
because of its continued existence without dramatic changes for
270 million years. (Hori et al., 1997). Its place of origin is believed
to be eastern China in Yangtze River Valley (Jaggy and Koch,
1997; Singh et al., 2008). From there, it became extensively
distributed in Asia, Europe, North America, and New Zealand
and is now widely cultivated (Kleijnen and Knipschild, 1992;
Hori et al., 1997; Belwal et al., 2019). A remark about its leaf
extract is included in the medical Dictionary of the Republic of
China (Kimbel, 1992; Kleijnen and Knipschild, 1992; Kressmann
et al., 2002). Ginkgo biloba is the only living species of theFrontiers in Pharmacology | www.frontiersin.org 11division Ginkgophyta probably due to its resistance to
environmental stresses (Deng et al., 2006; Cao et al., 2012).
Ginkgo biloba is one of the most sold medicinal plants. It is
one of the herbs mentioned in the Chinese Materia Medica more
than 5000 years ago, where its seeds and leaves—fresh or dried—
have been used for thousands of years in ancient herbal
medicine. Current research on its therapeutic properties
mainly uses Ginkgo biloba leaves and many pharmaceutical
companies including those in the USA and Europe
manufacture and sell extracts of the leaves (Kimbel, 1992;
Kleijnen and Knipschild, 1992; Kressmann et al., 2002). The
leaves can be used for the treatment of asthma and bronchitis in
the form of a tea that is most commonly used by the Chinese
people. More commonly, a standardized extract containing the
most active constituents can be made from the leaves and then
taken as a tablet, in liquid form, or given intravenously (Kleijnen
and Knipschild, 1992).
The main constituents of Gingko biloba are flavonoids
(ginkgo-flavone glycosides), terpenoids (ginkgolides and
bilobalides), biflavones, and organic acids among other
substances (Figure 3). Ginkgolides, being unique to Gingko
biloba, are not synthesized by any other living species.
Ginkgolides are classified into either A, B, C, J, or M types
(Figure 3). Gingko biloba flavonoids include severalA
B
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FIGURE 3 | Ginkgo biloba. (A) Leaves of Ginkgo biloba or Maiden Hair Tree (from https://pngtree.com/freepng). (B) Chemical structure of Ginkgolides. (C) Chemical
structure of Bilobalides. (D) Structural skeleton of flavonoids. R1 and R2 are side chains.April 2020 | Volume 11 | Article 422
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isorhamnetin (Figure 3). Flavonoids are known to reduce free
radical generation and terpenoids are known to reduce
inflammation and protect nerve cells against neuro-
inflammation (Kleijnen and Knipschild, 1992; Ude et al., 2013;
Isah, 2015). Through a multistep process, Ginkgo biloba dried
leaves extracts are enriched for flavonoids and terpenoids and the
unwanted substances are eliminated. At the final step, the liquid
extract is dried to give 1 part extract from 50 parts of raw drug
(leaves) (Kleijnen and Knipschild, 1992; Isah, 2015). The
composition of Gingko biloba extracts may differ depending on
the manufacturing process. Standardized extract forms have
been developed and usually contain 24–36% flavone glycosides
and 4–11% terpenoids. For example, standardized extract
EGb761 is the most commonly used Ginkgo biloba extract
(GBE), and it contains 24% ginkgo flavonoid glycosides, 6%
terpene lactones, and 5–10% organic acids (Kressmann et al.,
2002; Chan et al., 2007). These extracts have been used for
various therapeutic purposes, including regulation of cerebral
blood flow (Mashayekh et al., 2011), protection against free
radicals (Oyama et al., 1996; Bridi et al., 2001), tinnitus
treatment (Mahmoudian-Sani et al., 2017), protection of
neurons (Mahdy et al., 2011), as well as enhancement of
cognitive functions, such as memory and concentration
problems (Weinmann et al., 2010; Tan et al., 2015).
Ginkgo biloba at the Bench: Mechanism of
Action in CVDs
Ginkgo biloba's therapeutic effects and pharmacological actions
are majorly due to its constituent flavonoids (ginkgo-flavone
glycosides) and terpenoids (ginkgolides and bilobalide) (Lacour
et al., 1991). These Ginkgo biloba constituents are well known for
their antioxidant and anti-inflammatory effects. Ginkgo biloba
antioxidant and anti-inflammatory effects are beneficial in a
plethora of diseases that include cardiovascular, pulmonary,
and central nervous systems.
Free radical generation contributes to the development and
progression of numerous CVDs, including vascular injuries and
atherosclerotic plaque formation. During CVD pathogenesis, the
equilibrium between free radical generation and antioxidant
defense is greatly shifted toward the former (Singh and Niaz,
1996; Witztum and Berliner, 1998; Fulton and Barman, 2016).
GBE greatly restores the disturbed oxidative state equilibrium
due to their antioxidant action, which helps to scavenge excessive
free radicals as well as reduce free radical generation.
In addition, vasodilatory and antihypertensive properties of
GBE can exert cardioprotective benefits (Perez-Vizcaino et al.,
2009). In this regard, GBE has exhibited ACE inhibitory activities
(Mansour et al., 2011), activation of cholinergic pathways,
endothelial health improvement, inhibition of endothelium
activation and adhesion (Mesquita et al., 2017), and serum
lipid-lowering activities (Liou et al., 2015; Huang et al., 2018)
among other reported effects that are beneficial in CVD.
By acting as an anti-atherothrombotic and anti-inflammatory
agent, GBE can limit LPS-induced proliferation of VSMCs and
their morphological alterations. Furthermore, GBE can regulateFrontiers in Pharmacology | www.frontiersin.org 12the inflammatory response in blood vessels by decreasing the
activity of the ROS producing enzyme, nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (NOX), and reducing
the phosphorylation of mitogen-activated protein kinases
(MAPKs). Subsequently, MAPKs suppress toll-like-receptor-4
(TLR-4) expression in human aortic smooth muscle cells (Lin
et al., 2007). GBE can also decrease the production of the enzyme
involved in the rupture of atherosclerotic plaques, MMP-1, in
oxidized LDL- and 4-hydroxynonenal-induced human coronary
smooth muscle cells (Akiba et al., 2007). In the same model, the
GBE constituent, Ginkgolide B, attenuated endothelial
dysfunction by inhibiting monocyte chemotactic protein‐1
(MCP‐1), intercellular adhesion molecule‐1 (ICAM‐1), and
vascular cell adhesion molecule‐1 (VCAM‐1) production in
oxidized‐LDL‐induced HUVECs. Additionally, Ginkgolide B
treatment reduced the expression of several inflammatory
cytokines in oxidized‐LDL‐induced mouse RAW264.7
macrophages (Feng et al., 2018). Ginkgolide C, another GBE
constituent, can reduce adipogenesis and enhance lipolysis
leading to suppression of lipid accumulation. Ginkgolide C
treatment of 3T3-L1 adipocytes decreased the expression of
PPAR adipogenesis-related transcription factors. Ginkgolide C
also enhanced the Sirt1/AMPK pathway resulting in decreased
activity of acetyl-CoA carboxylase and fatty acid synthesis.
Moreover, Ginkgolide C stimulated the production of adipose
triglyceride lipase and hormone-sensitive lipase, leading to
elevated lipolysis levels (Liou et al., 2015). Similar results were
obtained with human HepG2 hepatocyte cell line (Huang
et al., 2018).
In Vivo Preclinical Evaluation of
Ginkgo biloba
Ginkgo biloba has several cardioprotective effects, including
improvement of atherosclerosis due to their ability to block
platelet-activating factor and platelet aggregation in rats (Zeng
et al., 2013; Huang et al., 2014).
eNOS is responsible for most of the vascular NO production,
and NO acts as a protective molecule to maintain vasculature
hemostasis and protection of the vascular endothelium
(Forstermann and Munzel, 2006). eNOS production and activity
are impaired in several CVDs, including hypertension (Chou et al.,
1998), cardiac hypertrophy (Ozaki et al., 2002), myocardial
infarction (Tsutsui et al., 2008), and heart failure (Couto et al.,
2015). GBE can act as an antihypertrophic agent by the activation of
the M2 muscarinic receptors/NO pathway and of cholinergic
signaling during cardiac hypertrophy. In a rat model of chronic
b-adrenergic stimulation-induced cardiac hypertrophy, GBE was
able to ameliorate the deleterious cardiac events associated with
cardiac hypertrophy. These effects were mediated by the
upregulation of M2 receptors and the downregulation of b1-
adrenergic receptors. GBE also restored eNOS activity and
consequently elevated NO levels (Mesquita et al., 2017). In
addition, the anti-hypertensive effects of EGb761 supplementation
were documented in hypertensive rats where SBP, DBP, and arterial
BP were reduced. EGb761 supplementation also decreased
inflammation and oxidative stress. While eNOS proteinApril 2020 | Volume 11 | Article 422
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decreased (Abdel-Zaher et al., 2018).
Vascular aging is commonly accompanied with low-grade
inflammation and degenerative structural changes and stiffness of
blood vessels and is considered a risk factor for the development of
CVDs, such as CHD and hypertension (Franceschi et al., 2000;
Lakatta and Levy, 2003). In the mesenteric arterioles of old rats,
GBE had a protective effect that alleviated arterial stiffness and
improved endothelial health (Cuong et al., 2019). In these aged
mesenteric arterioles, GBE improved vascular elasticity by
narrowing the EC gap, increasing curvature of inner elastic
membrane and reducing the middle collagen fiber layer. These
changes were accompanied by decreased phosphorylation levels of
Akt/FoxO3a signaling components, which usually contributes to
vascular dysfunction (Cuong et al., 2019).
Pre-treatment with EGb761 in rats that have undergone
myocardial ischemia–reperfusion injury inhibited the apoptosis of
myocardial cells, decreased the expression of caspase 3 and pro-
apoptotic Bax and increased that of anti-apoptotic Bcl-2, and
protected the myocardium by activating the endogenous Akt/Nrf2
antioxidant stress pathway. Akt/Nrf2 activation subsequently
decreased oxidative stress leading to reduced lipid peroxidation
and increased activities of the endogenous anti-oxidant defense
enzymes, namely SOD, and GSH-Px. In addition, EGb761 pre-
treatment increased the expression of the heat shock protein heme
oxygenase 1 (HO-1) and repressed the expression of mediators of
the inflammatory response, such as TNF-a, IL-6, and IL-1b (Chen
et al., 2019). HO-1 degrades heme (a potent oxidant) to generate
carbon monoxide, which has anti-inflammatory properties,
bilirubin, which is an antioxidant derived from biliverdin, and
iron (He et al., 2014). Similar Ginkgo biloba anti-oxidant
properties have been reported in diabetic rats as well.
Administration of GBE for 30 days can increase SOD, CAT, and
GSH-Px activity along with glutathione (GSH) levels in the liver and
pancreas of diabetic rats (Cheng et al., 2013). This enhanced anti-
oxidant status might be responsible for improved glucose uptake via
increased GLUT-4 expression (Shi et al., 2010). Furthermore,
EGb761 oral supplementation of HFD-fed mice can dose-
dependently enhance glucose tolerance, decrease insulin levels,
and diminish parameters of insulin resistance (Cong et al., 2011).
The above reports point that GBE has a pleiotropic mechanism
of action. Indeed, a metabolomic profiling study of the plasma and
hearts of GBE-supplemented rats with myocardial infarction
established that GBE acts via the regulation of multiple metabolic
pathways. Metabolomic profiles of rats with MI showed disturbed
metabolism in these rats because of modulated inflammatory
reaction, oxidative stress, and structurally damaged pathways.
However, GBE supplementation controlled the inflammatory
reaction and oxidative stress pathways by regulating sphingolipid,
phospholipid and glyceride metabolism and ameliorated the
structural damage by downregulating amino acid metabolism
(downregulation of urea cycle) and decreasing oxidative stress
(Wang et al., 2016).
In addition to the above-mentioned effects, GBE was able to
decrease calcium overload (Liu et al., 2013), the primary factor
responsible for the irreversible myocardial injury (Moens et al.,Frontiers in Pharmacology | www.frontiersin.org 132005). Rats with an ischemic myocardium and pre-treated with
GBE50, an extract that matches EGb761, exhibited decreased
intracellular calcium overload which could block arrhythmia.
GBE could decrease the calcium overload and protect from an
ischemic myocardium by inhibiting the Na+/Ca2+ exchanger (Liu
et al., 2013).
Ginkgo biloba to the Clinic
Given the above reported protective and therapeutic benefits of
GBE in vitro and in vivo, several clinical trials have been
conducted to test different formulations and doses of GBE in a
plethora of diseases (DeKosky et al., 2008; Gardner et al., 2008;
Kuller et al., 2010; Hashiguchi et al., 2015). A search of
clinicaltrials.gov shows that there have been 88 reported
clinical trials using various formulation of GBE. Of the 88
trials, 66 have been concluded, and there are 30 Phase 3 or 4
trials. Most of these trials dealt with neural and cognitive
disorders, where GBE has been shown to have clinical promise.
For GBE beneficial effects in CVDs, 7 out of the 88 trials were
concerned with vascular diseases, 4 with stroke, 4 with
arteriosclerosis, 2 with coronary disease, 1 with hypertension,
and 1 with atherosclerosis.
GBE has vasorelaxation effects in human subjects. GBE was
able to dilate forearm blood vessels causing changes in regional
blood flow without affecting BP levels in 16 healthy subjects
(Mehlsen et al., 2002). A small trial performed in normal
glucose-tolerant subjects to determine the effects of GBE on
glucose-stimulated pancreatic beta-cell function found that the
ingestion of GBE for three months can decrease SBP and DBP. In
these individuals, fasting plasma insulin and CRP were increased
(Kudolo, 2000). A double-blind, placebo-controlled, parallel
design trial was performed in patients with peripheral artery
disease aimed to assess the effects of the supplementation of 300
mg/day of EGb761 to treadmill walking time and cardiovascular
measures. In older adult patients, EGb761 produced a modest
non-significant increase in maximal treadmill walking time and
flow-mediated vasodilation. The authors suggested that a longer
duration might be needed to observe significant beneficial effects
(Gardner et al., 2008).
Kuller el al. used the Ginkgo Evaluation of Memory Study
(GEM) to assess CVD as a secondary outcome. The GEM study
was a double-blind trial that randomized 3069 participants
whose ages were over 75 years to 120 mg of EGb761 twice
daily (240 mg/day) or placebo. Data indicated that EGb761 did
not affect the originally assessed primary outcome—the
development of dementia or Alzheimer's disease (DeKosky
et al., 2008). Also, there were no differences in the incidence of
myocardial infarction, angina pectoris, or stroke between the
GBE and placebo groups. After 6 years of monitoring, the study
concluded that GBE does not reduce total CVD mortality or
CVD events (Kuller et al., 2010).
Several clinical trials to assess the protective effects of GBE in
CVDs are still ongoing. A 12-weeks randomized, double-blind,
phase 3 clinical trial aimed to further evaluate the safety and efficacy
of Rinexin® (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg)
which is widely used as an anti-platelet agent for the treatment ofApril 2020 | Volume 11 | Article 422
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recently, efficacy and safety of Ginkgo biloba pills for CHD patients
with impaired glucose regulation will be assessed in a Phase 4
randomized, double-blind, placebo-controlled clinical trial
(NCT03483779; clinicaltrials.gov). Twelve patients will be
recruited for a test period of 58 weeks. Pills of five different GBEs
will be to administered three times a day (Sun M. et al., 2018).
The therapeutic effect GBE appears to be more evident in
combination with modern medicine. The analysis of 23
randomized clinical trials (involving 2,529 patients) showed
that when combined with routine Western medicine, GBE was
more effective at the relief of angina pectoris as compared to the
routine medicine alone (Sun et al., 2015). In addition, due to its
platelet aggregation inhibitory effects, the combination of GBE
and modern medicine was reported to posses beneficial effects
against acute cerebral ischemia. In that study, platelet
aggregation was found to be significantly lower in patients
treated with ticlopidine and EGb 761 as compared with
patients treated with ticlopidine alone (Hong et al., 2013).
Combination of EGb 761 also had increased therapeutic effect
in patients with uncontrolled diabetes. Indeed, a randomized
controlled trial showed that the combination of EGb 761 with
metformin is more effective than metformin alone in improving
the outcomes of patients with uncontrolled T2DM (Aziz
et al., 2018).
The GBE therapeutic potential in managing CVDs has not
been always clinically observed. Using data obtained from the
GEM study database, Brinkley et al. concluded that GBE does not
reduce BP or the incidence of hypertension in older men and
women (Brinkley et al., 2010). In accordance, another study
reporting the analysis of 9 randomized clinical trials (1012
hypertensive patients) concluded that more rigorous trials are
needed to draw a conclusion on the efficacy of GBE in managing
hypertension (Xiong et al., 2014).
Based on these and other studies, the efficacy of GBE, despite
being reported in many studies, is best documented and observed
when combined with other known medications for the
management of CVDs.
Safety, Toxicity, and Side Effects of
G. biloba
Taken orally at the typical dosage, GBE may cause mild adverse
effects, principal among which are mild gastrointestinal upset,
headache, dizziness, constipation, and allergic skin reactions.
Higher dosages, however, can result in restlessness, diarrhea,
nausea, vomiting, and weakness (Diamond and Bailey, 2013).
Noticeably, the therapeutic employment of this herb is also
linked to adverse cardiovascular events. Fifteen published case
reports described a temporal association between GBE intake
and serious bleeding events, including intracranial bleeding
(Bent et al., 2005), an effect that may be attributed to the
platelet-activating factor antagonism exerted by ginkgolides,
bilobalides, and other constituents present in the extract (Izzo
and Ernst, 2009). These major bleeding events, including
subarachnoid and intracranial hemorrhage, have been mostly
described during the concomitant use of gingko and antiplateletFrontiers in Pharmacology | www.frontiersin.org 14and/or anticoagulant medications (Matthews, 1998). Therefore,
it is recommendable to stop GBE intake at least 2 weeks before
surgical procedures. Always because of its anti-platelet
properties, it has been suggested that GBEs (including seeds
and leaves) should be used with caution during pregnancy,
particularly around labor, and during lactation (Dugoua et al.,
2006). Several case reports described cardiac adverse events
associated with Ginkgo biloba leaf extracts. For example, 2
weeks GBE intake (40 mg, three times daily) has been reported
to develop ventricular arrhythmia in a 49-year-old subject with
good health (Cianfrocca et al., 2002), a symptom resolved upon
the discontinuation of GBE supplementation (Cianfrocca
et al., 2002).
A randomized placebo-controlled, double-blind pilot study of
GBE reported more ischemic stroke and transient ischemic
attack cases in the GBE group as compared with the placebo.
The study lasted 42-month 118 cognitively intact subjects
randomized to standardized GBE or placebo and its aim was
to measure the effect of GBE on cognitive decline (Dodge et al.,
2008). Another case report, attributed the frequent nocturnal
palpitations reported by a 35-year old woman taking GBE
supplementation to GBE (Russo et al., 2011). In addition to
clinical trials, Ginkgo biloba safety has also been assessed in vivo
in rats. Dietary intake of GBE (0.5% extract) for 4 weeks has been
reported to significantly reduce heart rate and blood flow velocity
in tail arteries of old spontaneously hypertensive (SH) rats as
compared to the control group (Tada et al., 2008). Thus, in the
elderly population with hypertension, the use of GBE may need
to be assessed for effects on heart rate (Mei et al., 2017).
Furthermore, some of the components (ginkgolic acids) of
EGb761 have been reported to elicit severe allergic reactions.
However, this allergic reaction is not present as long as the
carboxylic acid group of ginkgolic acids is intact (Chan et al.,
2007). Yet, contact with Ginkgo biloba plants is associated with
severe allergic reactions, including erythema and edema (Chiu
et al., 2002)
Food poisoning by Ginkgo biloba seeds has been reported in
Japan and China, where the main symptoms were convulsion,
vomiting, and loss of consciousness. The poisoning is primarily
due to the neurotoxic compound 4′-O-methylpyridoxine (MPN,
also known as ginkgotoxin) which interferes with pyridoxine
(vitamin B6) metabolism, leading to serious neurological
manifestations including neurotoxicity, seizures, and loss of
consciousness (Wada et al., 1988; Wada, 2005). Ginkgotoxin is
found in the ginkgo leaf at very low amounts. However, GBE is
unlikely to contain this toxic component as ginkgotoxin is
standardized to be too low in the extract (Arenz et al., 1996).
Several reports have described that GBE induces cytochrome
P450 (CYP) in humans, shedding light on potential interactions
between GBE and conventional drugs. Ginkgo biloba is known to
decrease the plasma concentrations of omeprazole, ritonavir, and
tolbutamide. It can interact with antiepileptics, acetylsalicylic
acid, diuretics, ibuprofen, risperidone, rofecoxib, trazodone, and
warfarin (Izzo and Ernst, 2009).
Considering that GBE is widely used in a plethora of diseases
combined with the paucity of data from animal studies regardingApril 2020 | Volume 11 | Article 422
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Health (NIH) has performed a 2-year and 3-month toxicity
and carcinogenicity study of GBE in B6C3F1/Nmice and F344/N
rats using different doses of GBE. The GBE used contained 24%
flavonol glycosides and 6% terpene lactones, along with no more
than five ppm ginkgolic acids. The study was performed by NIH
National Toxicology Program (NTP) and concluded that GBE
might elicit toxic and cancer-related consequences in rodents.
The carcinogenic effects reported were stomach ulcers, organ
modification including carcinogenic activity in the liver, liver and
thyroid gland hypertrophy, liver hyperplasia, and hyperkeratosis
(National Toxicology Program, 2013; Rider et al., 2014). These
reports raised concerns about the safety of GBE. Following the
NTP report, the International Agency for Research on Cancer
(IARC) reported in 2014 that there is inadequate evidence in
humans for the carcinogenicity of GBE (Grosse et al., 2013).
Following this report, clinical and genomic safety of IDN 5933/
Ginkgoselect®Plus, a standardized GBE, was assessed in elderly
subjects using a randomized placebo-controlled clinical trial. The
treatment group was given 120-mg IDN 5933 twice-daily for 6
months. No adverse clinical effects or increase of liver injury
markers were reported in the treatment group. Genomic testing
revealed that there is no difference in micronucleus frequency or
DNA breaks between the treated and placebo groups. The
expression of genes known to be modulated in early
carcinogenesis (c-myb, p53, and ctnnb1 [b-catenin]) was not
significantly different between groups at the beginning or the end
of the study (Bonassi et al., 2018). Taken together these results
support the safety of IDN 5933 at the used doses for a duration of
6 months. Overall, there is still controversy about the safety of
GBE for long-term use in human subjects and additional well-Frontiers in Pharmacology | www.frontiersin.org 15designed clinical trials that assess the safety and efficacy of GBE
are much needed.
GANODERMA LUCIDUM
Ganoderma lucidum, also known as “lingzhi” or “reishi,” is a
mushroom (Figure 4) whose different parts (mycelia, spores, and
fruit body) are used to make different forms of commercial G.
Lucidum for their medicinal benefits. Commercially, G. Lucidum
is available as powders, dietary supplements, tea, among other
forms. Historically, G. Lucidum medicinal use has been wide
spread in Asian countries (mainly in China, Japan, and Korea)
for more than 2000 years. Later, it was introduced to Western
societies (Ahmad, 2018). Hot water or ethanol can be used to
extract the bioactive compounds from the fruiting bodies, the
mycelia, or the spores of the mushroom (Heleno et al., 2012). A
wide array of bioactive compounds exist in G. Lucidum that
include triterpenes (Figure 4), polysaccharides, nucleosides,
steroids, fatty acids, alkaloids, proteins, peptides, amino acids,
and inorganic elements (Ahmad, 2018).
Immunomodulation, anti-oxidation, liver protection, anti-
proliferation, and anti-angiogenesis are among the various
properties that Ganoderma lucidum bioactive compounds
possess individually or synergistically (Sanodiya et al., 2009).
The triterpenoids have hepatoprotective, anti-hypertensive,
hypo-cholesterolemic, anti-histaminic, anti-tumor, and anti-
angiogenic effects. In addition, Ganoderma lucidum triterpenoids
have anti-platelet aggregation and complement inhibition effects.
It should be noted that G. Lucidum is the only source of triterpene
fatty acids called ganoderic acids. Of the 200 bioactive compounds
that have been identified in Ganoderma lucidum extracts,A
B
FIGURE 4 | Ganoderma lucidum. (A) Ganoderma lucidum (from https://pngtree.com/freepng). (B) Examples of the chemical structure of two Triterpenes from
Ganoderma lucidum.April 2020 | Volume 11 | Article 422
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et al., 1985; Tomoda et al., 1986), while ganoderic acids F, B, D, H,
K, S, and Y most likely have hypotensive effects (Morigiwa et al.,
1986). Ganoderma lucidum polysaccharides (b-d-glucans) harbor
anti-tumor properties due to their immunomodulation and anti-
angiogenesis effects. They also exhibit anti-oxidant protective
effects against free radicals and can decrease mutagen induced
cell damage (Boh et al., 2007). Ganoderma lucidum b-d-Glucan
polysaccharides were also identified as the active component in the
polysaccharide peptide (PsP) usually found in Ganoderma
lucidum extracts. There is no agreed dosage for G. lucidum,
however, commonly used doses vary between 1.5 and 9 g of
dried extract per day (Klupp et al., 2016).G. lucidum at the Bench: Mechanism of
Action in CVDs
As stated earlier, antioxidants are very important when it comes to
the prevention of atherosclerosis. G. lucidum can act as an
antioxidant; in the model organism Caenorhabditis elegans, G.
lucidum protected C. elegans against paraquat and heavy metal-
induced oxidative stress via the diet restriction pathway and the
mTOR/S6K signaling pathway, respectively (Cuong et al., 2019). G.
lucidum has been found to protect human lymphocyte DNA from
hydrogen peroxide-induced oxidative damage (Shi et al., 2002). It
was also found that G. lucidum regulates the expression of Nrf2
which in turn regulates antioxidants genes such as HO-1, GST,
NQO-1; G. lucidum ethanol extract enhanced the phosphorylation
of Nrf2 which upregulated HO-1 in C2C12 myoblasts (Lee Y. et al.,
2016). Thus, the antioxidant power in G. lucidum, which is
important for the prevention of atherosclerosis, can act on
different signaling pathways.
Elevated BP can be detrimental to heart function. Three peptides
(QLVP, QDVL, and QLDL), that can inhibit ACE activity and
called ACE inhibitory peptides (ACEIPs), were extracted from G.
lucidum and can be used to treat hypertension. QLVP can inhibit
ACE by its interaction with Gln242 and Lys472 of ACE. QLVP also
enhanced Angiotensin 1-mediated phosphorylation of eNOS and
reduced mRNA and protein expression of the vasoconstrictor
peptide endothelin-1 in HUVECs (Wu et al., 2019).
Selenium-enriched G. lucidum polysaccharide (Se-GLP) extracts
have protective effects against oxidative damage in a mouse model
of heart reperfusion injury. Se-GLP significantly reduced the
ischemic reperfusion injury-induced serum levels of MDA as well
as the levels of the proinflammatory molecule intercellular adhesion
molecule-1. Heart and serum levels of the antioxidant enzymes
SOD, CAT, and GSH-Px and the levels of GSH as well as total
antioxidant capacity were rescued by Se-GLP (Shi et al., 2010). In
another study, the protective effects of Ganoderic acid A, from G.
lucidum extracts, was found to activate the PI3K/AKT signaling
pathway causing increased proliferation and decreased apoptosis of
rat H9c2 cardiomyocytes exposed to hypoxic injury, a phenomenon
mediated by the activation of miR-182-5p and reduction of PTEN
expression (Zhang et al., 2018). Similarly, a preclinical study using
transverse aortic constriction mice as a model of pressure overload-
caused cardiomyopathy reported improved cardiac functionFrontiers in Pharmacology | www.frontiersin.org 16following treatment with spore oil extracted from G. Lucidum
(Xie et al., 2016).
More research needs to be conducted on the possible
mechanisms and signaling pathways that G. Lucidum bioactive
derivatives employ to elicit their beneficial effects in order to get a
more comprehensive sense of how these substances work.In Vivo Preclinical Evaluation of G. lucidum
To study the cardioprotective effects of G. lucidum extract, global
ischemia and reperfusion of isolated and perfused rat hearts were
used. As a preventative treatment, 400 mg/kg body weight of G.
lucidum extract was delivered to rats for 15 days. It was found that
this treatment halted the necrotic death of the rat cardiomyocytes
and reduced the reperfusion contracture (Lasukova et al., 2015).
Interestingly, G. lucidum extract supplementation attenuated
diastolic dysfunction and prevented irreversible cardiomyocyte
damage (Lasukova et al., 2008).
Diabetes mellitus is a metabolic disease that has been
correlated with a high incidence of CVDs, partly because high
blood glucose levels can cause vascular damage (Klein et al.,
2002; Fox et al., 2008; Shah et al., 2008). Thus, a supplement that
can help manage diabetes would be of great benefit to decrease
CVD risk. Thirty-five Wistar rats were supplemented with 50,
150, and 300 mg/kg of PsP from G. lucidum extracts. PsP
induced endothelial repair process with 300 mg/kg being the
most efficient dose. The findings showed that vascular damage
was improved by PsP treatment in a rat model of T2DM
(Heriansyah et al., 2019).
A diet high in fats is known to be a contributing risk factor to
the development of CVDs (Fleming, 2002) and weight loss is an
essential measure for the prevention of CVDs in obese people
(Sowers, 2003). The water extract of G. lucidum can reduce the
body weight, inflammation, and insulin resistance in HFD-fed
mice (Chang et al., 2015). In another study, G. lucidum spores
(GLSP) at a dose of 1 g/day supplemented orally for 4 weeks were
used in adult male Sprague-Dawley rats. GLSP decreased total
cholesterol and triglycerides in diabetic rats as well as attenuated
the levels of oxidative stress; it is worth noting that there was an
upregulation of genes related to lipid metabolism—acyl-CoA
oxidase 1 (ACOX1), acetyl-CoA carboxylase (ACC), and Insig-1/
2 gene expression. ACOX1 was activated more than 5-folds in
the GLSP-treated diabetic rats which indicates an accelerated
beta-oxidation of lipids in these rats (Wang et al., 2015).
Dyslipidemia is one of the major risk factors for CVDs
(Miller, 2009). In experimental animal studies, G. lucidum
showed anti-hyperlipidemic effects by lowering plasma total
cholesterol, LDL, and triglyceride levels (Chen et al., 2005).
Hydrogen peroxide free radicals are usually elevated during
dyslipidemia, and thus the risk of atherosclerosis, so
antioxidants are needed to prevent blood vessels damage. A
study conducted in high cholesterol diet-supplemented Wistar
rats that received 50, 150, and 300 mg/kg bodyweight of PsP
derived from G. Lucidum found that PsP acted as a potent
antioxidant. In addition, PsP may prevent the atherogenesis
process in the context of dyslipidemia with the optimum dose
being 300 mg/kg bodyweight (Wihastuti and Heriansyah, 2017).April 2020 | Volume 11 | Article 422
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Lucidum significantly reduced the body-weight increases of mice
fed an HFD suggesting its role as a hypolipidemic substance. In
addition, it exhibited antioxidant and antiapoptotic effects in the
HFD-fed mice (Liang et al., 2018).
With regard to regulation of high BP, a study conducted on
adult male hypertensive rats that received G. lucidum water
extracts intra-gastrically for seven weeks found that the
experimental rats BP was reduced to a level comparable to that
of rats on losartan (angiotensin II receptor antagonist) (Shevelev
et al., 2018)
G. lucidum to the Clinic
Antioxidants are potentially therapeutic substances that can be
used to prevent atherosclerosis as well as a variety of other
diseases. Several in vitro and in vivo preclinical studies have
shown that G. lucidum constituents possess antioxidant
activities, but evidence for such activities in human subjects was
lacking. Watchtel Galor et al. performed a follow-up study on the
effects of G. lucidum supplementation on an array of parameters
that included antioxidant biomarkers status and CHD risk. A
double-blinded, crossover, placebo-controlled intervention study
of 18 healthy people was conducted. There was an enhancement of
plasma total antioxidant markers status as well as an improvement
of CHD biomarkers after 10 days of supplementation. More
importantly, there was no renal, liver, or DNA toxicity
(Wachtel-Galor et al., 2004). To test G. Lucidum antioxidant
potential, a crossover human intervention study was conducted
on seven healthy people, and it was found that the plasma total
antioxidant power was enhanced after the administration of a
single dose of G. Lucidum extract. Lymphocytes harvested
following blood collection, however, showed no signs of
enhanced DNA repair (Wachtel-Galor et al., 2010). G. lucidum
PsP was also examined for its antioxidant properties. A clinical
trial was conducted with 37 high risk and 34 stable angina patients
that were given PsP 750 mg/day for 90 days. PsP proved to be a
potent antioxidant in the context of atherosclerosis in both the
high angina risk and stable groups. PsP supplemented groups
showed increased SOD, decreased MDA levels, and reduced
counts of circulating endothelial cells (CEC) and endothelial
progenitor cells (EPC) (Sargowo et al., 2018).
A double-blind, randomized, multicentered study was done
to evaluate the effects and safety of G. lucidum polysaccharides
on patients with CHD. Eighty-eight patients that constituted the
experimental group were given G. lucidum polysaccharides for
12 weeks. The polysaccharides significantly enhanced the
wellbeing of the patients evidenced as an improvement of their
major symptoms (chest pain, shortness of breath, palpitations),
and a decrease in BP and serum cholesterol levels (Gao et al.,
2004). Another study found that PsP from G. lucidum had anti-
inflammatory effects and vascular EC protection in patients with
ST-elevation myocardial infarction and non-ST-elevation
myocardial infarction with risk factors of dyslipidemia
(Sargowo et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 17A randomized clinical trial was conducted on the use of G.
lucidum for the treatment of cardiovascular risk factors of the
metabolic syndrome. It was reported that using G. lucidum (3 g/
d) for 16 weeks had no effect on glycosylated hemoglobin
(HbA1c) and fasting plasma glucose (FPG). Further,
consumption of G. lucidum was associated with the increased
risk of a subset of mild events including headache, fatigue, and
gastrointestinal events (Klupp et al., 2016).
None of the human studies reported above had any serious side
effects thus highlighting G. lucidum as a potential therapeutic and
preventative substance in the context of certain CVDs.
In a study examining 37 patients with high risk for
atherosclerosis and on an ongoing conventional CVD medication,
G. lucidum PsP was able to reduce the levels hs-CRP, IL-6, and
TNF-a, as well as the levels of MDA (Widya et al., 2016). Another
study involving 34 stable angina pectoris patients showed that
administration of PsP in combination with previous medication is
able to significantly reduce CECs and EPCs (markers for endothelial
vascular injury) as well as the levels of total cholesterol (Ubaidillah
et al., 2016).
The efficacy of G. lucidum in CVDs was tested in a prospective,
double-blind, placebo-controlled trial. Eighty-four volunteers with
T2DM and metabolic syndrome were supplemented with extracts
of G. lucidum, G. lucidum with Cordyceps sinensis, or placebo in
order to manage cardiovascular risk factors. Results from the study
evidenced that G. lucidum failed to provide benefit against CVDs in
patients with the metabolic syndrome (Klupp et al., 2016). Likewise,
the analysis of five trials (398 total volunteers), concluded that G
lucidumwas not effective in treating elevated BP (Klupp et al., 2015).
Taken together, these data suggest that G. lucidum is most
effective in providing cardiovascular protection when combined
with conventional CVDs medications.
Safety, Toxicity, and Side Effects of
G. lucidum
Numerous conducted studies and investigations pointed toward
the safety of G. Lucidum. In both male and female rodents, G.
lucidum shows no signs of toxicity even at a dose of up to 5000
mg/kg of body weight. No animal mortality was reported either
(Smina et al., 2011). When compared to doxorubicin (a typical
DNA intercalating agent used in chemotherapy), G. lucidum
extracts were shown to act indirectly on DNA, thus adding more
assurance to its safety (Gurovic et al., 2018).
Hemostatic parameters, platelet and global hemostatic
functions, were not affected when a dose of 1.5 g/d of G.
lucidum extract was given to healthy human volunteers for 4
weeks. In addition, the use of G. lucidum did not cause bleeding
problems in the healthy subjects (Kwok et al., 2005). However, in
another study, Tao and Feng volunteered 15 healthy subjects and
33 atherosclerotic patients and found that any dose above 3000
mg/day can inhibit platelet aggregation. As a result, caution is
advised when supplementing G. lucidum to patients with low
platelet count or patients that will undergo surgical procedures
(Tao and Feng, 1990).April 2020 | Volume 11 | Article 422
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G. lucidum was evaluated in Wistar rats and the results indicated
no evidence of abnormal clinical symptoms, death or significant
differences in body weight and food intake. No significant
differences were found in the hematology value, clinical
chemistry value and organ/body weight ratio. Additionally, no
mutagenicity was detected in Kunming mice (Zhang et al., 2016).
However, high doses of G. lucidum polysaccharides
modulated immune responses. The polysaccharides enhanced
the primary immune response to sheep red blood cells but did
not have significant effects on the phagocytic function or
macrophages (Zhang et al . , 2016). The G. lucidum
polysaccharides-modulated immune responses were tested in
another study where 16 participants supplemented with 2 g of
G. lucidum extract twice daily took part in a 10-day controlled
trial. In this study, there were no differences in CD4, CD8, and
CD19 levels in the blood, though CD56 did increase, without
achieving statistical significance, but it returned to baseline levels
10 days after intake of the extract (Wicks et al., 2007).
A 12-week trial performed on 23 dyslipidemic and mild
hypertensive volunteers revealed that Lingzhi (1.44 g/day) had
no effect on several clinical chemistry parameters as compared
with the placebo. However, symptoms such as headache,
influenza/running nose were found, although considered not
clinically significant (Chu et al., 2012).
Whether these changes that are induced by G. lucidum have
any clinical value remains to be addressed in future clinical trials
especially after long-term administration of escalating doses ofG.
lucidum extracts to assess long-term safety. Further studies are
still needed to examine the toxicity, side effects, and safety of G.
lucidum for human consumption.GYNOSTEMMA PENTAPHYLLUM
Gynostemma pentaphyllum (Figure 5), also known as Jiaogulan,
is a herbaceous climbing vine. Originating in south China and
now widely distributed in South and East Asia (Li et al., 2016), it
is found in subtropical China, Japan, Myanmar, and India (Chen
and Gilbert, 2006), growing near rivers and in the shade of forests
that surround Yangtze River basin and the southern areas of
China (Chen, 1995). It can be found as a health supplement in
beverages, biscuits, face washes, and bath oils (Li et al., 2016).
The herb has a low level of genetic diversity and a high level of
variation among populations (Zhang et al., 2019).
Phytochemical analysis found that G. pentaphyllum extracts
contain gypenoside saponins, flavonoids, polysaccharides, and
amino acids (Zheng, 2004; Nookabkaew et al., 2006; Yan et al.,
2013). Its biological effects can range from antimicrobial
(Srichana et al., 2011), antioxidant (Muller et al., 2012),
anticancer (Schild et al., 2010), anti-inflammatory (Wong et al.,
2017), antidiabetic (Yeo et al., 2008; Huyen et al., 2012),
antilipidemic (la Cour et al., 1995), and neuroprotective
(Keilhoff et al., 2017) to anti-obesity effects (Gauhar et al.,Frontiers in Pharmacology | www.frontiersin.org 182012; Park S. et al., 2014). It has been used to treat hepatitis
and hypertension (Lin et al., 2000). Among the various bioactive
compounds, dammarane-type triterpene saponins (gypenosides
or gynosaponins) are major (Kim and Han, 2011).
G. pentaphyllum at the Bench: Mechanism
of Action in CVDs
As already mentioned, antioxidants are important when it comes to
the prevention of atherosclerosis. Four flavonoids—namely
quercetin-3-O-(2″,6″-di-a-L-rhamnosyl)-b-D-galactopyranoside,
quercetin-3-O-(2″,6″-di-a-L-rhamnosyl)-b-D-glucopyranoside,
quercetin-3-O-(2″-a-L-rhamnosyl)-b-D-galactopyranoside, and
quercetin-3-O-(2″-a-L-rhamnosyl)-b-D-glucopyranoside—with
potent antioxidant effects against DPPH and OH free radicals, in
vitro, were found in the extracts of G. pentaphyllum. These
flavonoids also exhibited cytoprotection against AAPH-induced
oxidative damage in pig kidney LLC-PK1 cells by suppressing the
increase of MDA, and limiting the decrease of SOD and GSH (Lin
et al., 2019). In another study, flavonoids from G. pentaphyllum
were extracted and tested on human lung carcinoma A549 cells. It
was found that the flavonoids protected A549 cells against hydrogen
peroxide-induced oxidative damage by increasing the expression
levels members of the endogenous antioxidant system including
SOD, GSH, Nrf2, NQO1, and HO-1 (Wang et al., 2018). Another
study evaluated the antioxidant potential of one G. pentaphyllum
component, the phytoestrogen gypenoside XVII, it was found that
the phytoestrogen alleviated atherosclerosis via the ERa-mediated
PI3K/Akt pathway (Yang et al., 2017). A prior study evaluated the
effects of gypenosides of G. pentaphyllum on hydrogen peroxide-
induced oxidative damage in bovine pulmonary artery ECs. The
gypenosides protected the ECs from oxidative injury further
suggesting its potent antioxidant activity as well as its prospective
use as a preventative supplement against atherosclerosis (Li and
Lau, 1993).
Inflammation can contribute to the onset of atherosclerosis and
other CVD risk factors, hence, reducing inflammation can act as a
protective factor in CVDs. The gypenoside XLIX (Gyp-XLIX) from
G. pentaphyllum has been studied for its anti-inflammatory
properties. Gyp-XLIX inhibited LPS- and TNF-a-induced NF-kB
activation in THP-1 monocytes and in HUVECs. Gyp-XLIX
inhibition of NF-kB activation appears to be through a PPAR-a-
dependent pathway (Huang et al., 2006). On the other hand,
contradictory results were reported by Aktan et al., where G.
pentaphyllum gypenosides attenuated NF-kB activation. In fact,
the gypenosides extracted fromG. pentaphyllum could suppress NO
production by inhibiting iNOS activity and levels in murine
macrophages. Gypenoside-mediated decrement of iNOS protein
expression turned out to be mediated by the inhibition of NF-kB
activation (Aktan et al., 2003). In a different study, Tanner et al.
showed that G. pentaphyllum could elicit beneficial effects on
vascular function by acting as an inducer of eNOS (Tanner
et al., 1999).
Attenuating lipid accumulation may decrease CVDs incidence.
A study assessed the role of ombuine, a dual agonist of PPAR-a andApril 2020 | Volume 11 | Article 422
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glucopyranoside, a flavonoid from G. pentaphyllum, were applied
to HepG2 cells. Ombuine-stimulated HepG2 cells had activated
PPAR-a and PPAR-d/b, transcription factors that enhance lipolysis.
Ombuine-mediated activation of PPAR-a and PPAR-d/b
significantly reduced intracellular concentrations of triglyceride
and cholesterol as well as decreased lipogenic gene expression
witnessed as decreased levels of sterol regulatory element binding
protein-1c and stearoyl-CoA desaturase-1. These findings further
our understanding of howG. pentaphyllummay be involved in lipid
metabolism (Malek et al., 2013).
In a study that evaluated the role of total flavonoids of G.
pentaphyllum on apoptosis in cardiomyocytes of neonatal rats, it
was found that hypoxia-reoxygenation (H/R)-cardiomyocytes
had an increased protein expression of apoptosis-associated
Fas/FasL genes. Flavonoids of G. pentaphyllum could protect
cardiomyocytes against H/R injury by decreasing the production
of TNF-a and downregulating the protein levels of Fas/FasL
genes leading to inhibition of myocyte apoptosis (Le et al., 2007).
In Vivo Preclinical Evaluations of
G. pentaphyllum
Gypenosides are G. pentaphyllum key components with the
ability to help prevent atherosclerosis. The anti-atherosclerotic
effects of a mixture (HG) of Fermentum rubrum Hongqu and G.
pentaphyllum gypenosides were investigated in Wistar rats. The
study results revealed that the HG mixture had anti-
atherosclerotic effects that were better than statin, simvastatin,
treatment highlighting the anti-atherosclerotic potential of G.
pentaphyllum (Gou et al., 2018). In addition, HG alleviated
oxidative stress biomarkers by restoring antioxidant defense
components and decreasing the serum levels of anti-
inflammatory cytokines in male Sprague-Dawley rats with fatty
liver disease. The HG mixture in this study displayed athero-
protective characteristics (Gou et al., 2016).
Emphasizing the reported G. pentaphyllum gypenoside anti-
inflammatory and antioxidant capabilities, Yu et al. demonstrated
their beneficial effects in an ischemia–reperfusion injury rat model
where they were found to inhibit apoptosis. Ischemia–reperfusion
injury has detrimental outcomes in CHD. Yu et al. found that in
ischemia reperfusion injured-rats, the administration of
gypenosides decreased apoptotic rates as well as improved cardiac
function. Gypenosides inhibited ER-stress and apoptosis through
the blockade of the CHOP pathway and the activation of PI3K/Akt
pathway (Yu et al., 2016b). In a different study, it was demonstrated
that pretreatment with gypenosides limited the infarct size and
relieved ischemia reperfusion-induced pathological changes in the
myocardium, also in an ischemia reperfusion injury rat model.
Additionally, left ventricle function was preserved. Molecularly,
gypenosides pre-treatment reduced oxidative stress and restored
the antioxidant machinery in the myocardium. The cardio-
protective effects were also evidenced by the preservation of
mitochondrial function in myocytes. In this regard, the
maintenance of the mitochondrial membrane integrity inhibitedFrontiers in Pharmacology | www.frontiersin.org 19the release of cytochrome c from the mitochondria into the cytosol.
This further demonstrated the role of gypenosides from G.
pentaphyllum as a cytoprotective agent against acute myocardial
infarction and reperfusion injury (Yu et al., 2016a).
As elucidated to earlier, diabetes is positively correlated with
the development of CVDs. The effect of G. pentaphyllum extracts
on fasting blood sugar levels in diabetic mice was assessed. It was
found that the extracts had inhibitory effects on a-glucosidase
activity while affecting the protein expression of GLUT2 which
highlights its potential to manage diabetes (Wang et al., 2019).
Attenuating obesity, a risk factor for developing CVDs, may
decrease CVD incidence. G. pentaphyllum is largely used for the
management of diseases such as hyperlipidemia, fatty liver, and
obesity in China. G. pentaphyllum was found to affect lipid
metabolism and elicit anti-hyperlipidemic effects by elevating
the levels of phosphatidylcholine and decreasing the levels of
trimethylamine N-oxide in the plasma and liver of rats (Wang
et al., 2013). In addition, Gauhar et al. studied the effects of heat
processed ethanol extracts of G. pentaphyllum on obese mice.
They found that this extract decreased obesity in ob/ob mice by
activating the AMP-activated protein kinase (AMPK) pathway.
This study suggested a possible mechanism for fat-loss as well as
a potential for the use of G. pentaphyllum as a weight-loss
supplement (Gauhar et al., 2012). Gypenosides anti-
hyperlipidemic effects were examined in rats with poloxamer
P407-induced hyperlipidemia. Gypenosides at 250 mg/kg of
body weight was orally administered to hyperlipidemic rats.
Four and 12 days of gypenosides administration reduced
plasma triglycerides levels by 53% and 85%, respectively.
Similarly, total cholesterol levels were decreased by 10% and
44%, respectively. Interestingly enough, results were similar to
atorvastatin cholesterol-lowering statin drugs. Additionally, LDL
levels were reduced and HDL levels were increased by
gypenoside, which also reversed the poloxamer P407 inhibition
of lipoprotein lipase activity. This shows a promising therapeutic
potential of G. pentaphyllum for lowering high triglyceride and
cholesterol levels during acute hyperlipidemia (Megalli et al.,
2005). In accordance, extracts from the plant also decreased
triglyceride levels and LDL levels in obese Zucher rats (Megalli
et al., 2006). By employing a new extraction technique, Lee et al.
described some biological activity of a G. pentaphyllum extract
with a higher content of gypenoside L (1.8% w/w), gypenoside LI
(1.4% w/w), and ginsenoside Rg3 (0.15% w/w) (Lee et al., 2019b).
While HFD-fed mice showed significant clinical effects such as
increases in body weight, fat mass, white adipose tissue, and
adipocyte hypertrophy as compared to the control group, the
GPE-treated group failed to show them. GPE treatment also
reduced serum levels of triglyceride, total cholesterol, and LDL-
cholesterol, without affecting HDL-cholesterol. Mechanistically,
the clinically observed GPE effects appeared due to increased
AMPK activation and suppressed adipogenesis by decreasing the
mRNA levels of CCAAT/enhancer binding protein-a (C/EBPa),
PPARg, SREBP-1c, PPARg coactivator-1a, fatty acid synthase,
adipocyte protein 2, and sirtuin 1, and increased levels ofApril 2020 | Volume 11 | Article 422
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et al., 2019b).
G. pentaphyllum to the Clinic
In general, there are few human trials that addressed G.
pentaphyllum extract therapeutic effects or safety. A search on
clinicaltrials.gov shows that there are only four studies that use
G. pentaphyllum extracts. One of the studies is on obese patients
and three are on diabetes mellitus patients.
Actiponin, an extract of G. pentaphyllum, is a dietary
supplement used for weight loss in obese individuals. During an
interventional study, 80 randomized Korean participants took part
in a double blind, parallel study for 12 weeks where the
experimental group took Actiponin at a dose of 450 mg/day. The
experimental group lost weight with no adverse effects, as compared
to the placebo group (Park S. et al., 2014).
In another study, 1 mg/kg of the water extract of G.
pentaphyllum was given to 44 patients with CVDs and 56 healthy
individuals and the platelet aggregation was studied. It was revealed
that the water extract elicited significant inhibition of the
aggregation of platelets. This means that there is potential for the
use of this supplement to prevent cardio-cerebrovascular diseases
while being cautious not to give these supplements to patients who
suffer from low platelet count or bleeding disorders (Juan and
Shanzhang, 1995).
Some studies suggest there is a link between anxiety disorders
and an increased risk of developing a CVD (Fan et al., 2008;
Vogelzangs et al., 2010; Seldenrijk et al., 2011; Batelaan et al.,
2014). For this reason, it is of interest to reduce anxiety in order to
decrease the risk of developing CVD in predisposed individuals. It
was shown that G. pentaphyllum ethanol extract had anti-anxiety
effects on mice exposed to chronic stress (Choi H. et al., 2013).
This finding was replicated in a double-blind, placebo-controlled
clinical trial that had 72 healthy Korean individuals under chronic
stressful conditions. Thirty-six participants were given 200 mg of
G. pentaphyllum ethanol extract, twice a day for 8 weeks. The
supplementation reduced the experimental group anxiety without
any adverse drug effects suggesting its potential as a safe anti-
anxiety supplement (Choi et al., 2019).
Although the proven pharmacological effects of G.
pentaphyllum in in vitro studies and in vivo animal studies
may not necessarily translate well into efficacy human subjects,
there are positive studies. For instance, a set of studies conducted
in T2DM patients supplemented with G. pentaphyllum tea
showed improvements in insulin sensitivity and glycemia with
no adverse side effects (Huyen et al., 2010; Huyen et al., 2013). In
one of the trials, 24 drug-naïve T2DM patients were randomized
to take either 6 g daily of Gynostemma pentaphyllum tea or
placebo tea, during 1- week period. The authors measured FPG,
insulin levels, and HbA1c levels before, during, and after the
treatment. The study showed a prompt improvement of glycemia
and insulin sensitivity, and suggested that Gynostemma
pentaphyllum tea could be an effective, and safe approach to
treat T2DM patients (Huyen et al., 2010). The same authors
followed up with another study that used the same study designFrontiers in Pharmacology | www.frontiersin.org 20but enrolled only 16 drug-naïve T2DM patients. The authors
measured the same parameters and came to the same conclusion
that Gynostemma pentaphyllum tea exerted antidiabetic effects
by improving insulin sensitivity (Huyen et al., 2013). These
results were confirmed by another study where G.
pentaphyllum was used together with sulfonylurea (Huyen
et al., 2012). Thus far, the current data indicate that G.
pentaphyllum is quite efficient at improving insulin sensitivity
and blood sugar levels if administered solely and that its efficacy
may be enhanced when combined with other medications.Safety, Toxicity, and Side Effects of
G. pentaphyllum
In a study evaluating the toxicity of G. pentaphyllum extract on
female Sprague-Dawley rats, a single dose of up to 5000 mg/kg of
the extract was given and subchronic toxicity tests were performed
with 1000 mg/kg/day for 90 days. No rat death occurred nor did
any signs of toxicity arise. Blood chemistry values, though
statistically different from the control group, were within normal
ranges in rats. Thus, no mortality nor abnormalities have risen
from the G. pentaphyllum extract treatment (Chiranthanut et al.,
2013). In addition, no toxicity or mortality was reported upon
long-term administration of a dose up to 750 mg/kg body weight
of G. pentaphyllum in rats (Attawish et al., 2004).
A Phase I clinical trial was conducted to evaluate the safety of
G. pentaphyllum whereby three groups of healthy volunteers
were administered 50, 200, and 400 mg twice daily with water
extract of G. pentaphyllum for two months. No major immune
adverse events such as significant changes in natural killer cell
activities, number of CD3+, CD4+, and CD8+ cells, were
reported. No biochemical parameters were significantly affected
either. Such doses of G. pentaphyllum were deemed to be safe
(Chavalittumrong et al., 2007). In another clinical trial, 537
bronchitic patients were treated three times a day with G.
pentaphyllum (2.5–3 g, prepared as tablets or capsules).
Adverse side effects that included vomiting, abdomen tension,
diarrhea (or constipation), dizziness, blurred vision, and tinnitus
effects were seen in a small number of patients. Notably, these
symptoms were mild and did not stop the patients from taking
theG. pentaphyllum extract (Razmovski-Naumovski et al., 2005).
A very recent randomized, double-blind, placebo-controlled
clinical trial utilizing G. pentaphyllum extract in 72 healthy
adults revealed no adverse side effects of the ingestion of the
ethanolic extract of G. pentaphyllum (Choi et al., 2019). Overall,
consumption of G. pentaphyllum seems to be safe at the doses
required to observe a therapeutic effect.
CONCLUSION
Despite the abundance of knowledge regarding CVDs, CVD
prevalence continues to be on the rise. Thus, there is an
immediate demand for new safe, effective, and relatively cheap
drug candidates. Mounting evidence obtained from in vitro and
in vivo studies suggests that the four traditionally used medicinalApril 2020 | Volume 11 | Article 422
Shaito et al. Herbs as Drugs for Cardiovascular DiseasesFIGURE 6 | Herbal therapies in the context of CVDs. Herbal preparations can exert protective effects by ameliorating the pathological effects exerted by CVDs risk
factors. The herbal extracts can attenuate endothelial dysfunction and/or VSMC alterations by acting as, vasodilators, ROS scavengers, anti-oxidants, anti-
inflammatory, anti-apoptotic, anti-hypertrophic, or anti-proliferative agents. This achieved through mechanisms that act in ECs only, VSMCs only, or through
overlapping mechanism that act in both ECs and VSMCs. In ECs, herbal preparations can increase NO availability, decrease mitochondrial dysfunction and/or
metabolic abnormalities as well as enhance angiogenesis. This can decrease the incidence of atherosclerosis and hypertension, which in return can decrease the risk
of CVDs development. In VSMCs, the herbal extracts can modulate ECM deposition as well as cell migration, proliferation, and cell shape changes. VSMC, vascular
smooth muscle cell; ECM, extracellular matrix; EC, endothelial cell; NO, nitric oxide; PPARY, peroxisome proliferator-activated receptor-gamma.A B
FIGURE 5 | Gynostemma pentaphyllum. (A) Gynostemma pentaphyllum (Source https://pngtree.com/freepng). Examples of the chemical structure of Gynostemma
pentaphyllum Gypenoside that are usually synthesized 20 S-Protopanaxadiol (PPD). (B) example of some chemical structures of Gypenosides.Frontiers in Pharmacology | www.frontiersin.org April 2020 | Volume 11 | Article 42221
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Plant Mechanism of action References
Ginseng Bioactive/active fractions:
Rb1, Rg1, Rg3, Re, and Rd
Commonly used extracts:
Panax ginseng, Panax notoginseng, Panax
quinquefolium L., Panax japonicas
Improves lipid profile
• By acting as an agonist of PPAR
Controls hypertension and improve endothelial function
• By Inhibition of ACE
• By reducing adrenal catecholamines levels, elevating NO and
cGMP levels
• By activating Ca2+-gated potassium channels
Controls inflammation
• By inhibiting AP‐1 and NF‐kB
• By reducing COX‐2, IL‐6, IL‐1b, TNF‐a, CD68, MCP-1 and
MMP levels
Ameliorates oxidative stress
• By exhibiting free radical scavenging and metal ion chelating
abilities
• By promoting enhanced expression of antioxidant proteins,
such as Nrf2 and HO-1
Ameliorates mitochondrial dysfunction
Modulates angiogenesis
• By decreasing VEGF-A and FGF-2 levels
(Kim et al., 1999b; Keum et al.,
2003; Park et al., 2005; Persson
et al., 2006; Shin Y. et al., 2013;
Park J. et al., 2014; Lee H. et al.,
2016; Deng et al., 2017; Singh
et al., 2017; Lee et al., 2019a)
Gingko Biloba Bioactive/active fractions:
Ginkgolides classified into either A, B, C, J,
or M types
Commonly used extracts:
EGb761
Improves lipid profile
• By decreasing PPARs levels
Controls hypertension and improves endothelial function
• By decreasing ACE activity, activating cholinergic pathways,
limiting LPS-induced proliferation of VSMCs
• By decreasing ICAM‐1 and VCAM‐1 expression, decreasing
phosphorylation of Akt/FoxO3a
• By restoring eNOS activity, decreasing iNOS expression and
consequently elevating NO levels
Controls inflammation
• By suppressing TLR-4 expression
• By decreasing MMP-1, MCP-1, TNF-a, IL-6, or IL-1b
Ameliorates oxidative stress
• By decreasing NOX activity and level, activating endogenous
Akt/Nrf2 antioxidant stress pathway
• By increasing levels of HO-1, SOD and GSH-Px
• By reducing the phosphorylation of MAPKs
Prevents hypertrophy
• By activating M2 muscarinic receptors/NO pathway
• By decreasing calcium overload and inhibiting the Na+/Ca2+
exchanger
Prevents apoptosis
• By decreasing caspase 3 and pro-apoptotic Bax expression
and increasing anti-apoptotic Bcl-2 expression
(Akiba et al., 2007; Lin et al.,
2007; Mansour et al., 2011; Liu
et al., 2013; Liou et al., 2015;
Mesquita et al., 2017; Abdel-
Zaher et al., 2018; Huang et al.,
2018; Chen et al., 2019).
Ganoderma
lucidum
Bioactive/active fractions:
ganoderic acids A, B, C, D, F, H, K, S, and
Y, b-d-Glucan polysaccharides
Commonly used extracts:
Polysaccharide peptide (PsP) Ganoderma
lucidum
Controls hypertension and improves endothelial function
• By inhibition of ACE, enhancing Angiotensin 1-mediated
phosphorylation of eNOS
• By reducing the levels of vasoconstrictor peptide Endothelin-1
Improves lipid profile
• By upregulating lipid metabolism (ACOX1 and ACC)
Ameliorates oxidative stress and inflammation
• By enhancing phosphorylation of Nrf2 which upregulates HO-1,
GST, NQO-1, SOD, CAT, GSH-Px and GSH
• By decreasing the levels of MDA and ICAM, and regulation of
mTOR/S6K signaling pathways
Reduces necrosis
• By decreasing the levels of creatine phosphokinase
(Hikino et al., 1985; Tomoda
et al., 1986; Shi et al., 2002; Shi
et al., 2010; Lasukova et al.,
2015; Wang et al., 2015;
Wihastuti and Heriansyah, 2017;
Cuong et al., 2019; Wu et al.,
2019)
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cellular, molecular, and metabolic mechanisms that control
both CVDs pathogenesis and pathophysiology (Figure 6).
Here are presented the recent findings, advances, and studies
describing the therapeutic values of these plants in the context of
several CVDs. Current evidence demonstrates that these herbal
medicines have potent therapeutic properties and can ameliorate
pathological conditions associated with CVDs (Table 2 and
Figure 6). However, clear clinical therapeutic benefits have not
yet been secured. As such, these herbal treatments cannot be
safely recommended as an alternative therapeutic medicine. In
fact, the safety and toxicity of some of these plants have recently
raised potential concerns (eg. Gingko Biloba). We conclude that
better-designed studies and future clinical trials involving larger
sample sizes are needed to investigate the role of different
medicinal plants and their underlying mechanisms in theFrontiers in Pharmacology | www.frontiersin.org 23context of CVDs. Above all, the future clinical trials should
address the safety and toxicity of these herbal remedies.AUTHOR CONTRIBUTIONS
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Gynostemma
pentaphyllum
Bioactive/active fractions:
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